

PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE
THEREOF

The present invention relates to derivatives of pyridino-pyridinones substituted (i) in position 3 with an imidazole, itself substituted with a group R1 and substituted (ii) in position 7 with an aryl or heteroaryl, itself substituted optimally with a motif of the type $-[C(R3)(R4)]_m-CO-N(R5)(R6)$, to the preparation thereof and to the application thereof in therapeutics as inhibitors of kinase activity of receptors for PDGF (platelet derived growth factors) ligands and optionally of receptors for the FLT3 (fms-like tyrosine kinase receptor) ligand.

The FLT3 and PDGF-R receptors are members of class III of the family of tyrosine kinase receptors (TKR), which also includes the stem cell factor receptor (c-kit) and M-CSF receptor (c-fms). They are characterized by an extracellular domain composed of 5 immunoglobulin-like domains containing the ligand binding region, a transmembrane domain, and an intracellular moiety composed of a juxtamembrane domain, a kinase domain split in two by an insert domain (split domain) (Ullrich & Schlessinger, 1990).

The fixation of ligands on the TKR induces dimerization of the receptors, and activation of their tyrosine kinase moiety which leads to transphosphorylation of tyrosine residues (Weiss & Schlessinger, 1998). These phosphorylated residues thus serve as a point of anchorage for the intracellular signalling proteins which *in fine* cause various cellular responses: maintenance, division, proliferation, differentiation, or even cellular migration. (Claesson-Welsh, 1994).

The gene coding for FLT3 is located on chromosome 13q12 (Rosnet et al., 1992) and codes for the FLT3 protein (CD135 antigen) expressed specifically by the haematopoietic cells and more particularly the immature cells such as haematopoietic stem cells and myeloid and lymphoid multipotent progenitors and its expression disappears in the course of haematopoietic differentiation. Its ligand, the FLT3 Ligand, induces dimerization of the receptor, followed by autophosphorylation of the intracellular moiety of the receptor which leads to activation of the signalling cascade. The effects of activation of the receptor by its ligand are the survival and expansion of the multipotent

- 2 -

progenitors.

Two isoforms of receptors to the PDGFs have been identified, the chain PDGF-Ralpha and the chain PDGF-Rbeta, which following fixation of their ligands are homo- or heterodimerized and induce intracellular signalling. The receptors to the PDGFs are
5 essentially expressed by the cells of mesenchymatous origin and are notably found on fibroblasts, smooth muscle cells, pericytes and glial cells (Ross et al., 1986, Heldin, 1992).

Platelet Derived Growth Factor, PDGF, a protein with a molecular weight of about 30 000 dalton, is secreted essentially by the platelets, and secondarily by the
10 endothelium, vascular smooth muscles and monocytes. It is formed from two polypeptide chains joined together by disulphide bridges forming either homodimers, or heterodimers. Four genes (7p22, 22q13, 4q31 and 11q22) have been described as coding for 4 different polypeptide chains (A, B, C and D), which once dimerized give five biologically active ligands PDGF-AA, BB, CC, DD and AB (for review, Yu et al., 2003).
15 There is specificity of binding, including notably PDGF-AA for the alpha isoform of the receptor, PDGF-D for the BB form, and PDGF-C for the alpha and alpha/beta form. The PDGF ligands are potent mitogens, but are also involved in phenomena of migration, survival, apoptosis and cellular transformation.

20 Inhibitors of the PDGF-R alpha, beta and FLT3 function are involved in various therapeutic areas. The physiopathological phenomena in which these receptors may be involved include liquid cancers or leukaemias, solid cancers with or without metastases targeting tumour cells and/or cells of the tumour environment (vascular, fibroblastic), fibroses and vascular diseases:

25

A. Liquid cancers

The leukaemias are of various types and affect either the myeloid compartment or the lymphoid compartment.

Expression of FLT3 in leukaemic cells derived from acute myeloid leukaemias (AML) is
30 of the order of 100% of cases, and FLT3 thus contributes to stimulation of survival and proliferation of leukaemic cells (Carow et al., 1996; Drexler et al., 1996, Stacchini et al., 1996).

- 3 -

Moreover, FLT3 is the site of activating mutations in 22 to 30% of adult AMLs and 11% of childhood AMLs. Most often it involves in-tandem duplications (ITD) in the transmembrane region of the receptor (more particularly exons 14 and 15). These mutations conserve the reading frame and their size can vary between 18 and 111 base
5 pairs. More rarely in about 7% of AMLs, a point mutation is found on the D835 residue located in the kinase domain. In the majority of cases, the FLT3 ITD forms have a greater risk of relapse and are markers of low survival prognosis. These two types of mutations lead to constitutive activity of the kinase domain independent of stimulation by the ligand and have been shown to transform haematopoietic cells *in vitro* and *in vivo*
10 (Mizuki et al., 2000; Tse et al., 2000). Kelly et al., (2002) gave an elegant demonstration, in a model of bone marrow reconstitution in the mouse, that FLT3 ITD causes a myeloproliferative syndrome.

The advantage of using inhibitors of tyrosine kinase activity has been reported both *in*
15 *vitro* and *in vivo* by several teams, and recently in the model of bone marrow reconstitution FLT3 ITD, such an inhibitor was shown to be capable of inducing regression of the tumour and of increasing the survival rate of the animals (Ofarrel, 2003).

Moreover, recent data demonstrate the advantage of combining said inhibitors with
20 cytotoxic agents such as daunorubicin (Levis et al., 2004).

Interestingly, blast cells of the AML type can also overexpress other receptors with kinase activity such as c-kit or even PDGF-R.

25 Myeloproliferative/dysplastic syndromes

Quite frequently, cytogenetic abnormalities resulting from chromosomal translocations have been reported in myeloproliferative syndromes. These rearrangements generate deregulated fusion proteins with tyrosine kinase activity involved in the proliferation of myeloid blast cells.

30

-fusion proteins with kinase activity PDGF-R beta

The fusion proteins with kinase activity PDGF-R beta are constituted of the intracellular

- 4 -

moiety of PDGF-R-beta and in addition a domain N-ter of another protein (generally a transcription factor). The following have been reported notably in chronic myelomonocytic leukaemias (CMML): Rab5/PDGF-Rbeta, H4-PDGF-Rbeta, HIP1-PDGF-RB or Tel/PDGF-R beta. The latter is the most represented. It is derived from the translocation t(5; 12)(q31; p12) and codes for a fusion protein constituted of the N-terminal part of the transcription factor Tel and the C-terminal part of PDGF-Rbeta. An oligomerization domain present in the Tel part leads to a dimerized form of the fusion protein and to the constitutive activity of the kinase domain. This protein has been shown *in vitro* to be capable of transforming haematopoietic cells on many occasions and notably in detail in the article by M. Carrol et al. (PNAS, 1996, 93, 14845-14850). *In vivo*, this fusion protein leads to a hyperproliferation syndrome of the myeloid cells (Ritchie et al., 1999).

Moreover, in animals, and in clinical practice in humans, it has been shown that inhibitors of tyrosine kinase activity inhibit the proliferation of blast cells and can halt the process of leukaemogenesis.

-fusion proteins with kinase activity PDGF-R alpha

Two fusion proteins involving PDGF-R alpha have been reported: bcr-PDGF-Ralpha present in an atypical chronic myeloid leukaemia (CML) and FIP1L1-PDGF-Ralpha found in a subpopulation of leukaemias, the LEC "eosinophilic leukaemias", arising from a hyper-eosinophilia syndrome (Griffin et al., 2003). This fusion protein bears constitutive activity of the kinase domain of PDGF-R alpha and is responsible for the anarchic proliferation of these cells.

Inhibitors of the kinase activity of PDGF-R alpha have shown efficacy on the proliferation of FIP1L1-PDGF-R alpha positive cells and recently an inhibitor compound has received the indication for HES/CEL.

Thus, inhibiting the kinase activity of PDGF-Ralpha and beta and the FLT3wt and FLT3ITD activity, as is done by the compounds of the invention, proves to be of therapeutic interest for AMLs.

Apart from AMLs and myeloproliferative syndromes, other leukaemias can be interesting

- 5 -

for targeting with such inhibitors, including B-ALL and T-ALL (acute lymphoid-B or lymphoid-T leukaemias), where FLT3 is also expressed. Moreover, by virtue of normal expression of FLT3 on haematopoietic stem cells and the demonstration of its expression on leukaemic stem cells, inhibitors of the kinase activity of FLT3 might prove
5 beneficial in all leukaemias (including the CMLs) where the role of leukaemic stem cells in relapse where resistance is involved.

B. Solid cancers

10 Inhibitors of the tyrosine kinase activity of the PDGF-R alpha and beta receptors may be of interest for solid cancers either by directly targeting the tumour cell, which through an autocrine or paracrine mechanism is sensitive to the TK inhibitory activity of PDGF-R, or by targeting cells in the surroundings by destabilizing the network for promoting combination with other therapeutic agents.

15

-Examples of solid cancers in which the target is the tumour cell

* *Soft cancer: Ewing sarcoma*

Ewing sarcoma is a form of bone cancer which mainly affects children and young adults
20 (the average age is 13 years). It covers 10% of primary bone tumours and the risk of metastasis is high. It is a rare tumour affecting 2 to 3 persons per million inhabitants per year. The tumour cells are characterized by a chromosomal translocation t(11; 22) coding for the fusion protein EWS/FLI1.

The cells responsible are those of the mesenchyma, which express the PDGF-R-beta
25 receptor which induces the motility and growth of the Ewing sarcoma cells under stimulation by PDGF-BB (Üren et al., 2003). Moreover, Zwerner and May (2001) have demonstrated expression of PDGF-C by the Ewing sarcoma cells.

These same cells also express the receptor TKR c-kit and it has been shown that an inhibitor of the kinase activity of PDGF-R and c-kit is capable of inhibiting tumour growth
30 of Ewing sarcoma lines in a mouse model of xenograft (Merchant et al., 2002).

* *Tumour of connective tissue (GIST, dermatofibrosarcoma)*

- GISTs (gastrointestinal stromal tumours)

Fletcher's group (2004) considered the 15% of GISTs in which KIT is neither mutated nor overexpressed (KIT-wt). These authors observed strong overexpression of the PDGF-R alpha receptor. This situation is encountered in about a third of these GIST KIT-wt. As for mutations of PDGFRA, the authors observe them (35%) in cases where KIT is normal. Mutated PDGFRA have high tyrosine kinase activity and are constitutive and affect aspartic acid in position 842. In the same way as for Ewing sarcomas, two inhibitors of the kinase activity of c-kit and PDGF-R have shown efficacy *in vitro* and *in vivo* on the proliferation of PDGF-R alpha mutated cells (Le Tourneau et al., 2007; Corless et al., 2005).

- dermatofibrosarcomas (of Darier and Ferrand or protuberans or DFSP)

Darier and Ferrand dermatofibrosarcoma (or DFSP) is a skin tumour with fusiform cells of intermediate malignity characterized by slow progression with a major risk of recurrence in the case of insufficient exeresis. A genetic abnormality present in 95% of cases was discovered in 1990, notably with identification of the translocation of chromosomes 17 and 22 t(17-22)(q22; q13) which leads to fusion of genes COL1A1 and PDGF B and a large amount of PDGFB overexpresses its tyrosine kinase receptor, PDGFR. Inhibiting the kinase activity of PDGF-R is a promising therapy since this leads *in vitro* to inhibition of proliferation and apoptosis of tumour cells and *in vivo* this permits reduction of tumour growth in models of tumour grafting in immunodeficient mice (Sjöblom T et al., 2001). Moreover, clinical studies have demonstrated the efficacy (complete or total remission) of such a molecule in DFSPs (for review see McArthur, 2007).

* *Gliomas and Glioblastomas:*

Glioblastoma is the commonest brain tumour and the most aggressive with a median survival of around 1 year. PDGFs and their receptors (alpha and beta) are frequently expressed in gliomas. The possibility exists that an autocrine/paracrine loop may contribute to the pathogenicity of these tumours. The PDGF-R-alpha receptor is expressed preferentially in the cells of the tumour, whereas the PDGF-beta receptor is

- 7 -

expressed preferentially in the vascular endothelial cells of the tumour. Blocking the kinase activity of PDGF-R has demonstrated its efficacy 1) *in vitro* by reducing the number of colonies on soft agar and inhibiting the proliferation of cell lines 2) on reduction of tumour growth in models of grafts in the nude mouse 3) in combination with
5 irradiation in models of intracranial grafts of cells of glioblastoma lines (Oerbel et al., 2006; Geng et al., 2005, Strawn et al., 1994, Chin et al., 1997).

Thus, the compounds of the invention are of interest for Ewing sarcomas, GISTs, dermatofibrosarcomas but also desmoid tumours, haemangiomas and other
10 fibrosarcomas for which data on expression of PDGF-R are available.

C. Targeting PDGF-R in the tumour environment

Angiogenesis

The cells in the environment around the tumour form an integral part of the development
15 of cancer whether in the case of a primary tumour or secondary tumour (metastases). Among the cells in the environment that express PDGF-R and for which the role of this receptor has been demonstrated, we find the mural cells of vessels, i.e. pericytes and smooth muscle cells but also activated fibroblasts.

Angiogenesis is a process of generation of new capillary vessels from preexisting
20 vessels or by mobilization and differentiation of bone marrow cells. Thus, both uncontrolled proliferation of endothelial cells and mobilization of angioblasts from bone marrow are observed in processes of neovascularization of tumours. It has been shown *in vitro* and *in vivo* that several growth factors stimulate endothelial proliferation such as VEGF and FGFs. In addition to these mechanisms, it has also been demonstrated that
25 mural cells such as pericytes and smooth muscle cells contribute to stabilization of newly formed vessels. Invalidation of PDGF-R beta causes a deficit of pericytes in the mouse and leads to death of the animals at the end of gestation due to micro-haemorrhages and oedemas (Hellström et al., 1999, Hellström et al., 2001). In an elegant study of transplantation, expression of PDGF-R-beta by pericytes was shown to
30 be necessary for their recruitment in tumour vessels by retention of PDGF-B by the endothelial cells but also by the PDGF-B secreted by the tumour cells (Abramsson et al., 2003). In the transgenic model Rip1Tag2 of pancreatic tumour, Song et al. also

demonstrated expression of PDGF-R beta on the perivascular progenitors in the marrow derived from bone marrow, and these progenitors differentiate into mature pericytes around the tumour.

The advantage of blocking the activity of PDGF-R on the tumour pericytes was demonstrated by using the inhibitor of the tyrosine kinase activity of PDGF-R in animal models (transgenic model of tumour of the pancreas and implantation of glioma tumour), and the effect on tumour growth proves to be considerable in combination with an inhibitor of the kinase activity of VEGF-R (Bergers et al., 2003). Data in the literature (Cao et al., 2002, Fons et al., 2004) demonstrated the involvement of PDGF-R alpha and of PDGF-C in angiogenesis and in the differentiation of endothelial progenitors to cells such as pericytes and smooth muscle cells.

Activated fibroblasts

PDGF-R is abundant in the tumoral stroma and is found on activated fibroblasts (myofibroblasts). It was shown in two studies that the combination of inhibitors or antagonists of PDGF-R with cytotoxic agents leads to a decrease in the microdensity of the vessels of ovarian cancers (Apte et al., 2004) and of pancreatic cancers (Hwang et al., 2003). PDGF-R beta regulates the pressure of the interstitial tissue of the tumour (Heuchel et al., 1999) and the co-administration of inhibitors of PDGF-R and chemotherapeutic agents improves their delivery into the tumour cells by reducing the intratumoral pressure (Griffon-Etienne, 1999). Finally in a murine model, administration of an inhibitor of the kinase activity of PDGF-R improves the consumption of chemotherapeutic agents by the tumour and thus increases their efficacy (Griffon-Etienne, 1999; Pietras et al., 2002; Pietras et al., 2003). These effects are most probably the effect of the TAFs (tumour-associated fibroblasts), also called CAFs (carcinoma-associated fibroblasts), activated fibroblasts present around the tumour which express PDGF-R, as illustrated by the recent works of Hwang et al., (2008), Kain et al. (2008), Pietras et al. (2008) in in-vivo models of pancreatic cancer and of cervical carcinogenesis. Stimulation by the PDGF ligand produced by the tumour cells stimulates the fibroblasts that produce the extracellular matrix and thus increase the interstitial tension. Furthermore, reducing this tension can facilitate delivery of drugs into the tumour and thus increase their efficacy. The activated fibroblasts present in the tumoral

stroma therefore represent a novel therapeutic target in oncology (for review see Bouzin & Feron, 2007).

Metastases

- 5 Several works indicate that the PDGF-R and PDGF-ligand couple is involved in the development of metastases, probably by their action on angiogenesis and metastasization by the blood circulation, but also by a direct effect on lymphangiogenesis and therefore the metastases that are spread by the lymphatic vessels. A review notably documents the direct role of PDGF-BB in lymphangiogenesis
10 and lymphatic metastases (Cao et al., 2005). However, most works implicate expression of PDGF-R in the environment of the metastases which promote the establishment and development of secondary tumours. The example most frequently reported is the development of bone metastases.

** Example of prostate cancer:*

- 15 Bone is frequently the site of metastases. 85 to 100% of patients who die from prostate cancer have bone metastases. Chemotherapy improves survival without progression and overall survival but because of the extreme heterogeneity of bone metastases in one and the same patient, chemotherapy does not provide a cure. It was shown using a model of immunodeficient mice that PDGF-BB plays an important role in the
20 development of osteoblastic bone metastases *in vivo* (Yu et al., 2003). As for PDGF-DD, it speeds up the growth of prostate tumour cells and increases their interaction with the cells of the stroma. Expression of the PDGF alpha and beta receptor has been demonstrated respectively in 62 and 75% of prostate cancers. Moreover, an immunohistochemical study showed that the prostatic tumour and its metastases
25 expressed PDGF-R (Hwang et al., 2003). Kim et al., (2003) showed that PDGF-R is expressed on bone metastases and on the vascular endothelial cells dependent on the metastases. An inhibitor of tyrosine kinase of PDGF-R combined with a cytotoxic agent substantially reduces bone metastases of prostate cancer in a murine model (Uehara et al., 2003). Moreover, this same combination leads to apoptosis of tumour cells, of
30 vascular endothelial cells and inhibition of the growth of tumour cells in bone. Blocking of these receptors and of their signalling pathways in bone constitutes a novel therapeutic approach (Hwang et al., 2003; Uehara et al., 2003). In humans, clinical trials have

shown the benefit offered by the combination of inhibitor of PDGF-R and of cytotoxic agent in patients with hormone-resistant prostate cancers with bone metastases. A decrease of the marker (prostate-specific antigen) PSA > 50% was in fact observed in 38% of patients. The mean duration of PSA response was 8 months and the survival
5 time without progression was 11 months.

Based on these various works, it appears that the compounds of the invention are of interest for the treatment of solid cancers by their effect on the surrounding cells, in combination with other therapeutic agents such as cytotoxic agents or inhibitors of angiogenesis.

10

D. Fibroses

Fibroses are often the cause of a primary event such as a cancer, treatment by radiotherapy, hepatitis, alcoholaeemia. Involvement of PDGF is clearly demonstrated in pulmonary fibrosis (including asbestosis), renal fibrosis (glomerulonephritis), marrow
15 fibrosis (often associated with megakaryocytic leukaemias), induced by radiotherapy as well as hepatic and pancreatic fibrosis (connected with alcoholaeemia or with hepatitis) (for review see JC Bonner, 2004). Overexpression of PDGF was notably clearly shown, and results in *in-vivo* models with inhibitors of TK activity of PDGF-R have also been reported. Among these studies, that of Einter et al., (2002) showed that PDGF-CC is a
20 potent inducer of renal fibrosis. The authors tested the efficacy of a neutralizing antibody in a model of unilateral urethral ligature, in which fibrosis develops particularly rapidly. They observed a very pronounced antifibrotic effect with a reduction in accumulation of myofibroblasts, a reduction in accumulation of extracellular matrix and a reduction in deposits of collagen IV. Another study conducted in a model of bleomycin-induced
25 pulmonary fibrosis in the mouse showed the efficacy of an inhibitor of the TK activity of PDGF-R on prevention of fibrosis by inhibition of proliferation of mesenchymal cells (Aono et al., 2005). In a model of asbestos-induced fibrosis, an inhibitor of PDGF-R TK reduced the progression of fibrosis in the pulmonary parenchyma and the deposition of collagen (Vuorinen K, Gao F, Oury TD, Kinnula VL, Myllärniemi M. Imatinib mesylate
30 inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp Lung Res. 2007 Sep; 33(7):357-73). Several teams have demonstrated involvement of PDGF-R in hepatic fibrosis. It has been clearly demonstrated that PDGFBB and DD possess pro-

fibrogenic characteristics on hepatic stellate cells (Rovida et al., 2008; Borkham-Kamphorst et al., 2007). In vivo, an inhibitor of PDGF-R TK is capable of reducing early fibrogenesis in a model of ligation of the biliary duct in the rat (Neef et al., 2006).

- 5 Thus, in view of the data in the literature, the compounds of the invention appear to be of therapeutic interest for various types of fibrosis.

E. Vascular diseases: atherosclerosis and restenosis, arteriosclerosis

- The proliferation and migration of vascular smooth muscle cells contribute to intimal
10 hypertrophy of the arteries and thus play a predominant role in atherosclerosis and in restenosis after angioplasty and endarterectomy. It was clearly demonstrated *in vitro* and *in vivo* in animal models that PDGF is involved in these phenomena. In vivo, it was notably shown that there is increased expression of PDGF in a vein graft model in the pig. Moreover, it was also shown that an inhibitor of the TK activity of PDGF-R
15 consistently reduced the size of lesions of the thoracic and abdominal artery of ApoE-KO diabetic mice (animals treated with streptozotocin). Another study showed that inhibition of signalling induced by PDGF (TK or PDGF A antisense) leads to a decrease in neointima formation in "balloon injury" and "coronary artery restenosis" models. (Deguchi J, 1999, Ferns et al., 1991, Sirois et al., 1997, Lindner et al., 1995)

20

- Thus, inhibitors of the tyrosine kinase activity of PDGF-R, such as the compounds of the present invention, represent a therapy of choice, either alone, or in combination with compounds that are antagonists of other growth factors involved in these pathologies such as FGF, in the treatment of pathologies connected with proliferation of vascular
25 smooth muscle cells such as atherosclerosis, post-angioplasty restenosis or following placement of endovascular prostheses (stents) or during aorto-coronary bypasses.

By virtue of their inhibitory activity on the TK activity of PDGF-R, the compounds of the invention appear to be of interest for treating these vascular diseases.

30

F. Others

Other pathologies appear to be possible indications for the compounds of the invention,


- including idiopathic pulmonary arterial hypertension (PAH). PAH, characterized by a significant and sustained increase in pressure in the pulmonary artery, leads to right ventricular heart failure and often to patient death. It is associated with increase in the proliferation and migration of smooth muscle cells of the pulmonary vessels. Schermuly et al., (2005) showed that inhibition of the tyrosine kinase activity of the PDGF receptors greatly improves the progression of the disease. For this, among other things they used a model of experimental pulmonary arterial hypertension in the rat, obtained by administration of monocrotaline for 28 days. All the treated rats survived, whereas 50% of those in the untreated control group died.
- 10 The compounds of the invention might also be of therapeutic interest in pathologies of the eye. On the one hand, they might contribute to prevention of post-operative fibrosis in the case of cicatricial lesions of the cornea and of keratoconus. This could be explained by their action on proliferation of myofibroblasts as reported recently by Kaur et al., (2009). Moreover, they might also promote neovascular regression for pathologies
- 15 such as ARMD (age-related macular degeneration). This was in fact demonstrated by several teams in experimental models, including notably Jo et al.; Dell et al., in 2006.

The present invention relates to derivatives of pyridino-pyridinones substituted (i) in position 3 with an imidazole itself substituted with a group R1 and substituted (ii) in position 7 with an aryl or heteroaryl, itself substituted optimally with a motif of the type $-[C(R3)(R4)]_m-CO-N(R5)(R6)$. The present invention also relates to the preparation of said compounds and application thereof in therapeutics as inhibitors of the kinase activity of receptors for PDGF (platelet derived growth factors) ligands and optionally of

25 receptors for the FLT3 (fms-like tyrosine kinase receptor) ligand.

The present invention relates to compounds corresponding to formula (I):

- 13 -



in which,

R1 represents a hydrogen atom or a (C₁-C₄)alkyl group;

5 **R2** represents a group -(CH₂)_n-B where:

- n'=0, 1, 2, 3 or 4; and
- B represents (i) a (C₃-C₅)cycloalkyl group or a (C₁-C₄)alkyl group, said group being optionally substituted with one or more fluorine atoms, or (ii) a (C₁-C₄)alkoxy group;

10

Y, Z, V and **W** represent, independently of one another:

- a -CH- group,
- a carbon atom optionally substituted with a group R7, said group R7 representing a (C₁-C₄)alkyl group or a halogen atom,
- 15 • a heteroatom such as a nitrogen atom, a sulphur atom or an oxygen atom, or
- no atom,

it being understood that the ring in which V, W, Y and Z are comprised is a ring comprising 5 or 6 ring members, it being understood that the dotted lines in said ring
20 indicate that the resultant ring is an aromatic ring and it being understood that said ring comprises 0, 1 or 2 heteroatoms;

R3 and **R4** represent, independently of one another, groups that may be identical or different, R3 and R4 being selected from:

- 25
- a hydrogen atom; and
 - a linear (C₁-C₄)alkyl group;

- 14 -

or **R3** and **R4** form, together with the carbon to which they are bound, a (C₃-C₅) cycloalkyl group;

m is an integer equal to 1, 2, 3 or 4;

R5 represents a hydrogen atom or a (C₁-C₄)alkyl group;

R6 represents a group -(CH₂)_n-L in which:

- n = 0, 1, 2 or 3, and
- **L** is a group selected from the following groups:
 - an aryl comprising 6 carbon atoms;
 - a heteroaryl comprising between 5 and 6 ring members and comprising at least one heteroatom selected from nitrogen, oxygen and sulphur;
 - a saturated heterocycle comprising 5, 6 or 7 ring members and comprising at least one heteroatom selected from nitrogen and oxygen, said heterocycle being optionally a lactam;said aryl, heteroaryl or heterocyclic group being optionally substituted with at least one substituent selected from (i) linear or branched (C₁-C₄)alkyl groups, (ii) (C₃-C₅)cycloalkyl groups, (iii) halogen atoms, (iv) aryls and (v) benzyl;

it being understood that when **L** is a heteroaryl or a heterocycle, said heteroaryl or heterocycle comprising at least one nitrogen atom, the latter can optionally be substituted with said substituent;

or **R5** and **R6** form, together with the nitrogen atom to which they are bound, a heterocyclic group, optionally substituted with at least

- a heteroaryl, or
- a (C₁-C₃)alkyl group, which can itself be substituted with a heterocycle comprising 5 or 6 atoms and comprising at least one heteroatom selected from nitrogen and oxygen, it being understood that when it is a

- 15 -

heterocycle comprising at least one nitrogen atom, the latter can optionally be substituted;
said compound of formula (I), its enantiomers and diastereoisomers, including mixtures thereof, being in the form of a base or a salt of addition to an acid, for example such as
5 trifluoroacetic acid (TFA) or hydrochloric acid and/or in the form of solvate.

The compounds of formula (I) can comprise one or more asymmetric carbon atoms. They can therefore exist in the form of enantiomers or of diastereoisomers. These enantiomers, diastereoisomers, as well as mixtures thereof, including racemic
10 mixtures, form part of the invention. For example, when L represents a heterocycle, the absolute configuration of a carbon substituted on said heterocycle can be R or S, or when **R3** is different from **R4**.

The compounds of formula (I) can exist in the form of bases or of salts of addition to an
15 acid or to acids. Said salts of addition form part of the invention. These salts can be prepared with pharmaceutically acceptable acids, but salts of other acids that may be used for example for purification or isolation of the compounds of formula (I) also form part of the invention.

20 The compounds of formula (I) can also exist in the form of solvates, namely in the form of associations or of combinations with one or more molecules of solvent. Said solvates also form part of the invention.

Within the scope of the present invention, the following definitions are used:

- 25 ➤ alkyl group: a saturated aliphatic group comprising 1 to 7 carbon atoms (advantageously, a saturated aliphatic group comprising 1 to 4 carbon atoms and abbreviated to (C₁-C₄)alkyl) and being linear or, when the alkyl chain comprises at least 3 carbon atoms, possibly being branched or cyclic. As examples, we may mention methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, methyl-cyclopropyl, pentyl, 2,2-
30 dimethylpropyl, hexyl and heptyl groups, as well as the cycloalkyl groups defined below;
- cycloalkyl group: a cyclic alkyl group comprising 3 to 7 carbon atoms (advantageously from 3 to 5 carbon atoms) and in which all the carbon atoms are

inserted in the ring. We may mention the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl groups;

- alkoxy group: an -O-alkyl group, where the alkyl group is as defined above;
- 5 ➤ halogen atom: a fluorine, a chlorine, a bromine or an iodine atom;
- haloalkyl group: a group comprising an alkyl group as defined above in which one or more hydrogen atoms have been substituted with one or more halogen atoms as defined above; thus, the term fluoroalkyl is used when the halogen in question is fluorine,
- 10 ➤ heteroatom: a nitrogen, oxygen or sulphur atom;
- aryl group: a monocyclic aromatic group comprising 6 ring members, for example a phenyl group;
- heteroaryl group: a monocyclic aromatic group comprising between 5 and 7 ring members including between 1 and 3 heteroatoms as defined previously. As
- 15 examples, we may mention the pyridine, pyrazine, pyrimidine, imidazole, pyrrole, pyrazole, thiophene, thiazole, isothiazole, thiadiazole, oxazole and isoxazole groups;
- heterocyclic group: a cyclic alkyl group comprising between 5 and 7 ring members including one or more heteroatoms as defined previously. As examples, we may mention the pyrrolidine, morpholine, piperidine, piperazine and tetrahydrofuran
- 20 groups.

The aforementioned groups can be substituted, knowing moreover that in the case of heteroaryl or heterocyclic groups comprising at least one nitrogen atom, substitution can take place on this nitrogen atom when such a substitution proves chemically

25 possible.

Among the compounds of formula (I) according to the invention, we may mention compounds for which:

30 **R5** represents a hydrogen atom or a methyl, or **R5** and **R6** form, together with the nitrogen atom to which they are bound, a heterocyclic group, optionally substituted with at least

- a heteroaryl, advantageously a pyridine; or

- a (C₁-C₃)alkyl group, which can itself be substituted with a heterocycle comprising 5 or 6 atoms and comprising at least one heteroatom selected from nitrogen and oxygen, advantageously it is a C₁alkyl group, itself substituted with a heterocycle comprising 5 atoms including a nitrogen atom;

5

and/or

m is equal to 0, 1 or 3,

and/or

R3 and R4 represent, independently of one another, groups that may be identical or different, R3 and R4 being selected from:

10

- a hydrogen atom, and
- a methyl,

and/or

Y, Z, V and W represent, independently of one another:

15

- a -CH- group;
- a carbon atom substituted with a group R7, said group R7 representing a (C₁-C₄)alkyl group or a fluorine atom; or
- a heteroatom such as a nitrogen atom, a sulphur atom or an oxygen atom, advantageously a nitrogen atom,

20 and/or

R1 represents a hydrogen atom or a methyl,

and/or

R2 represents a group -(CH₂)_n-B where:

25

- n'=0, 1 or 3; and/or
- B represents (i) a (C₃-C₅)cycloalkyl group, (ii) a (C₁-C₄)alkyl group or (iii) a (C₁-C₄)alkoxy group,

and/or

the compounds of formula (I) in the form of a base or of a salt of addition to an acid such as hydrochloric acid or trifluoroacetic acid.

30

- 18 -

Among the compounds of formula (I) according to the invention, a first subgroup of compounds consists of compounds for which:

R6 represents a group $-(CH_2)_n-L$ in which:

- $n = 0, 1, 2$ or 3 , and
 - 5 • **L** is a group selected from the following groups:
 - a heteroaryl comprising 5 ring members and comprising (i) 2 heteroatoms selected, independently of one another, from nitrogen, oxygen and sulphur, or (ii) 3 heteroatoms selected, independently of one another, from nitrogen and sulphur,
 - 10 ○ a heteroaryl comprising 6 ring members and comprising 1 or 2 heteroatom(s),
 - a heterocycle comprising 5 ring members and comprising a heteroatom selected from nitrogen and oxygen, said heterocycle being optionally a lactam, and
 - 15 ○ a heterocycle comprising 6 ring members and comprising 2 heteroatoms selected from nitrogen and oxygen,
- said heteroaryl group or heterocycle being optionally substituted with at least one substituent selected from (i) linear or branched (C_1-C_4) alkyl groups, (ii) (C_3-C_5) cycloalkyl groups, (iii) halogen atoms, (iv) aryls and (v) benzyl,
- 20 it being understood that when **L** is a heteroaryl or a heterocycle, said heteroaryl or heterocycle comprising at least one nitrogen atom, the latter can optionally be substituted with said substituent.

Among the compounds of formula (I) according to the invention, a second subgroup
25 of compounds consists of compounds for which **L** is:

- a heteroaryl comprising 6 ring members selected from pyridine, pyrazine, pyridazine and pyrimidine, or
- an aryl such as phenyl, or
- a heteroaryl comprising 5 ring members selected from thiazole, imidazole,
30 pyrazole, isoxazole and 1,3,4-thiadiazole, or

- a saturated heterocycle comprising 5 ring members selected from pyrrolidine, tetrahydrofuran and 2-oxo-pyrrolidine, or
 - a saturated heterocycle comprising 6 ring members selected from morpholine, piperazine and piperidine,
- 5 said aryl, heteroaryl or heterocyclic group being optionally substituted with at least one substituent selected from (i) linear or branched (C₁-C₄)alkyl groups, (ii) (C₃-C₅)cycloalkyl groups and (iii) aryls,
- it being understood that when L is a heteroaryl or a heterocycle, said heteroaryl or heterocycle comprising at least one nitrogen atom, the latter can optionally be
- 10 substituted with said substituent.

Among the compounds of formula (I) according to the invention, a third subgroup of compounds consists of compounds for which L is selected from:

- pyridine, optionally substituted with at least one linear or branched (C₁-C₄)alkyl group,
- morpholine, optionally substituted with at least (i) a (C₃-C₅)cycloalkyl group or (ii) a linear or branched (C₁-C₄)alkyl group,
- a pyrrolidine, optionally substituted with at least (i) a linear or branched (C₁-C₄)alkyl group, or (ii) a benzyl,
- a thiazole, optionally substituted with at least (i) a linear or branched (C₁-C₄)alkyl group, or (ii) a chlorine atom,
- an imidazole, optionally substituted with at least one linear or branched (C₁-C₄)alkyl group,
- a gamma-lactam,
- a 1,3,4-thiadiazole, optionally substituted with at least (i) a linear or branched (C₁-C₄)alkyl group, or (ii) a (C₃-C₅)cycloalkyl group,
- an isoxazole, optionally substituted with at least one linear or branched (C₁-C₄)alkyl group,
- a pyrazole, optionally substituted with at least one linear or branched (C₁-C₄)alkyl group,
- a pyrazine,

- 20 -

- an isothiazole, optionally substituted with at least one linear or branched (C₁-C₄)alkyl group,
 - a phenyl,
 - a tetrahydrofuran,
- 5 it being understood that when L is a heteroaryl or a heterocycle, said heteroaryl or heterocycle comprising at least one nitrogen atom, the latter can optionally be substituted.

Among the compounds of formula (I) according to the invention, we may notably
10 mention the following compounds:

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-2-yl-acetamide (compound 1)

2-{6-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-pyridin-3-yl}-N-pyridin-2-yl-acetamide (compound 2)

15 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-cyclopropyl-morpholin-3-ylmethyl)-acetamide (compound 3)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-isopropyl-morpholin-3-ylmethyl)-acetamide (compound 4)

2-Amino-1-ethyl-3-(1H-imidazol-2-yl)-7-{4-[2-oxo-2-((S)-2-pyrrolidin-1-ylmethyl-
20 pyrrolidin-1-yl)-ethyl]-phenyl}-1H-[1,8]naphthyridin-4-one (compound 5)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-pyridin-4-yl-ethyl)-acetamide (compound 6)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-methyl-N-(2-pyridin-4-yl-ethyl)-acetamide (compound 7)

25 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-methyl-thiazol-2-yl)-acetamide (compound 8)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-3-methyl-phenyl}-N-(1-ethyl-pyrrolidin-2-ylmethyl)-acetamide (compound 9)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-
30 yl]-phenyl}-N-(6-methyl-pyridin-3-yl)-acetamide (compound 10)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-

yl]-phenyl)-N-(1,3-dimethyl-1H-pyrazol-4-ylmethyl)-acetamide (compound 11)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-thiazol-2-ylmethyl-acetamide (compound 12)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-oxo-pyrrolidin-2-ylmethyl)-acetamide (compound 13)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-methyl-[1,3,4]thiadiazol-2-yl)-acetamide (compound 14)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-[1,3,4]thiadiazol-2-yl-acetamide (compound 15)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3-methyl-isoxazol-5-yl)-acetamide (compound 16)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-acetamide (compound 17)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-methyl-thiazol-2-yl)-acetamide (compound 18)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide (compound 19)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-cyclopropyl-[1,3,4]thiadiazol-2-yl)-acetamide (compound 20)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-pyridin-3-yl-ethyl)-acetamide (compound 21)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2,5-dimethyl-2H-pyrazol-3-ylmethyl)-acetamide (compound 22)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(1-methyl-1H-imidazol-4-ylmethyl)-acetamide (compound 23)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyrazin-2-yl-acetamide (compound 24)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-pyridin-2-yl-ethyl)-acetamide (compound 25)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-chloro-thiazol-2-yl)-acetamide (compound 26)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-

- yl]-phenyl)-N-(3,4-dimethyl-isoxazol-5-yl)-acetamide (compound 27)
2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-methyl-pyridin-4-yl)-acetamide (compound 28)
2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyrazin-2-ylmethyl-acetamide (compound 29)
2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-ethyl-[1,3,4]thiadiazol-2-yl)-acetamide (compound 30)
2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(tetrahydro-furan-2-ylmethyl)-acetamide (compound 31)
2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3-methyl-pyridin-2-yl)-acetamide (compound 32)
2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-methyl-pyridin-2-yl)-acetamide (compound 33)
2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4,6-dimethyl-pyridin-2-yl)-acetamide (compound 34)
2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(6-methyl-pyridin-2-yl)-acetamide (compound 35)
2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-3-ylmethyl-acetamide (compound 36)
2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-ethyl-2H-pyrazol-3-yl)-acetamide (compound 37)
2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3-methyl-isothiazol-5-yl)-acetamide (compound 38)
2-Amino-1-ethyl-3-(1H-imidazol-2-yl)-7-{4-[2-oxo-2-(2-pyridin-3-yl-pyrrolidin-1-yl)-ethyl]-phenyl}-1H-[1,8]naphthyridin-4-one (compound 39)
2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(1-benzyl-pyrrolidin-3-yl)-acetamide (compound 40)
2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-[(S)-1-(tetrahydro-furan-2-yl)methyl]-acetamide (compound 41)
2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-methyl-pyridin-3-yl)-acetamide (compound 42)
2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-

yl]-phenyl}-N-(4-ethyl-pyridin-2-yl)-acetamide (compound 43)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-ethyl-N-pyridin-4-ylmethyl-acetamide (compound 44)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(6-ethyl-pyridin-2-yl)-acetamide (compound 45)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-benzyl-acetamide (compound 46)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-propionamide (compound 47)

4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-N-pyridin-4-ylmethyl-benzamide (compound 48)

4-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-butylamide (compound 49)

2-{4-[7-Amino-8-ethyl-6-(4-methyl-1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide (compound 50)

2-{4-[7-Amino-8-cyclopropylmethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide (compound 51)

2-{4-[7-Amino-8-cyclopentyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide (compound 52)

2-{5-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-pyridin-2-yl}-N-pyridin-4-ylmethyl-acetamide (compound 53)

2-{4-[7-Amino-6-(1H-imidazol-2-yl)-8-(3-methoxy-propyl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide (compound 54)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3-phenyl-propyl)-acetamide (compound 55)

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-2-fluoro-phenyl}-N-(1-ethyl-pyrrolidin-2-ylmethyl)-acetamide (compound 56)

It should be noted that the above compounds were named in IUPAC nomenclature using the Autonom software.


Hereinafter, protecting group, denoted by Pg, means a group that makes it

possible, on the one hand, to protect a reactive function such as a hydroxy or an amine during a synthesis and, on the other hand, to regenerate the intact reactive function at the end of synthesis. Examples of protecting groups as well as methods of protection and deprotection are given, for example, in "Protective Groups in Organic Synthesis",
 5 Green et al., 2nd Edition (John Wiley & Sons, Inc., New York), 1991.

Leaving group means, hereinafter, a group that can be easily cleaved from a molecule by rupture of a heterolytic bond, with departure of an electron pair. This group can thus be replaced easily with another group during a substitution reaction, for example. Said
 10 leaving groups are, for example, halogens or an activated hydroxyl group such as a methanesulphonate, benzenesulphonate, p-toluenesulphonate, triflate, acetate, etc. Examples of leaving groups as well as references for their preparation are given in "Advances in Organic Chemistry", J. March, 3rd Edition, Wiley Interscience, 1985, p. 310-316.

15

According to the invention, the compounds of general formula (I) can be prepared according to the method described in the following schemes 1, 2 and 3.

Scheme 1

20

According to scheme 1, in stage (i), a 2,6-dihalogeno-nicotinic acid of formula (II)

is mono-substituted in position 2 with an amine of formula R_2-NH_2 (where R_2 is as defined previously with reference to the compounds of formula (I)), at room temperature, or at a temperature from 50°C to 100°C, with conventional heating or microwave heating and in a protic solvent such as an alcohol, for example ethanol, n-butanol, *tert*-butanol or
5 water. The acid (III), resulting from stage (i), is then activated to a derivative of formula (IV), following stage (ii) either in the form of acid fluoride by the action of cyanuryl fluoride at room temperature, in the presence of a base such as triethylamine or pyridine and in an aprotic solvent such as dichloromethane or THF, as described by G. OLAH et al., in *Synthesis* (1973), 487, or in the form of imidazolidine by the action of
10 carbodiimidazole in a polar aprotic solvent such as DMF or THF or by other methods known by a person skilled in the art, such as those described by MUKAIYAMA and TANAKA in *Chem. Lett.* (1976), 303 or by ISHIKAWA and SASAKI in *Chem. Lett.* (1976), 1407.


The cyanoacetylimidazoles of formula (V) are prepared in two stages from an
15 imidazole-2-carboxaldehyde unsubstituted or substituted in position (4,5) of the imidazole. In stage (iii) the free nitrogen of the imidazole-2-carboxaldehyde is protected by a protecting group, designated Pg in scheme 1, for example such as a SEM, Boc or trityl group, in conventional working conditions known by a person skilled in the art "Protective Groups in Organic Synthesis", Green et al., 2nd Edition (John Wiley & Sons,
20 Inc., New York). If applicable, the two isomers τ and π of the protected imidazole are obtained and used without distinction in the subsequent reactions. The protected imidazole-2-carboxaldehyde is then transformed in stage (iv) to cyanoacetylimidazole of formula (V) by reaction of the aldehyde function with the anion of TOSMIC, formed by adding potassium *tert*-butylate to anhydrous DME at low temperature (-50°C), followed
25 by ring opening of the anionic intermediate formed, 4-tosyl-2-oxazoline, then the reaction mixture is heated under reflux in the presence of methanol to permit formation of the acetylnitrile function following the method described by Van Leusen A. et al. (*Synthetic Comm*, 10(5) 1980, 399-403).

The acid fluoride or the imidazolidine of formula (IV) obtained at the end of stage
30 (ii), very reactive but stable, is then reacted, in stage (v), with a cyanoacetylimidazole of formula (V), unsubstituted or substituted in position (4,5), in the presence of one equivalent of a base such as sodium hydride or potassium *tert*-butoxide, in a polar

aprotic solvent such as THF or DMF, at a temperature from -5°C to room temperature, then a second equivalent of the base used is added and the compound of formula (VI) that formed is cyclized in situ, at room temperature, to give the pyridino-pyridinone compound of formula (VII), following stage (vi).

5 The halogenated intermediate of formula (VII) can then be transformed to the pyridino[2,3-b]pyridinone-7-stannous derivative of formula (VIII), by reacting it, in stage (vii), with a hexaalkyldistannous compound, where the alkyl can be either a butyl or a methyl, in the presence of a complex of palladium (in oxidation state (0) or (II)) for example such as $\text{Pd}(\text{PPh}_3)_4$, $\text{PdCl}_2(\text{PPh}_3)_2$, and optionally with addition of a ligand such
10 as triphenyl arsine, trifurylphosphine in a polar or nonpolar solvent such as dioxane, THF, DMF or a nonpolar solvent such as toluene at a temperature between 50 and 110°C according to the methodology described by Stille JK et al., (JACS, 1987, 109, 813).

To obtain the compounds of formula (I) according to the present invention, two
15 methods can be used starting from the halogenated intermediate of formula (VII), according to method 1 described in scheme 2, or starting from the stannous compound of formula (VIII), according to method 2 described in scheme 3.

Scheme 2

- 5 Following method 1 described in **scheme 2**, the intermediate (VII) is used in stage (viii) in a Suzuki coupling reaction with a boronic acid [formula (IXa) with $\text{M} = -\text{B}(\text{OH})_2$] or a boronic ester of pinacol [formula (IXa) with Pg being a protecting group as defined previously, $\text{M} = \text{B}(\text{OC}(\text{CH}_3)_2)_2$] where m , R_1 , R_2 , R_3 , R_4 , V , W , Y and Z are as defined previously with reference to the compounds of formula (I)
- 10 according to the invention, it being understood that the ring must comprise between 5 and 6 ring members, and G is either a $(\text{C}_1\text{-C}_4)$ alkoxy group such as OEt or a motif $-\text{NR}_5\text{R}_6$, where R_5 and R_6 are as defined for the compound of formula (I). These

compounds (IXa) are either commercial or are prepared from the corresponding halogenated derivatives according to the method of Miyaura et al. (*Chem Rev* 1995, 95, 2457).

This reaction (viii) is carried out in the presence of a complex of palladium (in oxidation state (0) or (II)) for example such as $\text{Pd}(\text{PPh}_3)_4$, $\text{PdCl}_2(\text{PPh}_3)_2$, Pd_2dba_3 , Xphos or $\text{PdCl}_2(\text{dppf})$, in a protic or aprotic polar solvent such as DME, ethanol, DMF, dioxane, or mixtures of these solvents, in the presence of a base such as caesium carbonate, aqueous sodium hydrogen carbonate, or K_3PO_4 , heating conventionally between 80 and 120°C or by microwave heating between 130 and 170°C.

10

In the case when G is a motif NR_5R_6 , where R_5 and R_6 are as defined for the compound of formula (I), it is **route 1** that is followed, leading to compound (X), which after a conventional stage of deprotection, for example in the presence of an acid such as HCl (4N) in dioxane or trifluoroacetic acid in a solvent such as ethanol or dichloromethane, at a temperature between -5°C and 60°C, gives the compound of formula (I) according to the invention.

In the case when G is a $(\text{C}_1\text{-C}_4)$ alkoxy group such as OEt, it is **route 2** that is followed, the compound (XI), obtained by Suzuki coupling in stage (viii), is saponified in stage (ix) in the presence of LiOH or NaOH, in a mixture of protic solvent such as water, methanol or ethanol and of aprotic solvent such as THF or DMF, at room temperature or by heating to a temperature between 50 and 100°C, to give compound (XII). The latter is then used in a peptide coupling reaction with the amine HNR_5R_6 , where R_5 and R_6 are as defined for the compound of formula (I), in stage (x), in the presence of a coupling agent such as BTUT, BTUH or CDI and a base, for example diisopropylethylamine or NaHCO_3 , in an aprotic solvent such as dichloromethane, THF or DMF or by other methods known by a person skilled in the art, such as those described in "Principles of Peptide Synthesis", 2nd Ed 1993 M Bodanszky, Springer Laboratory, to give the compound of formula (XIII), which after a conventional stage of deprotection, as described previously, gives the compound of formula (I) according to the invention.

30

According to method 2 described in **scheme 3**, compound (VIII) is used in a Stille coupling reaction with a halogenated derivative of formula (IXb) where Pg, m, R_1 , R_2 ,

R3, R4, V, W, Y and Z are as defined previously with reference to the compounds of formula (I) according to the invention, it being understood that the ring must comprise between 5 and 6 ring members, X is a halogen atom and G is either a (C₁-C₄)alkoxy group such as OEt or a motif -NR₅R₆, where R₅ and R₆ are as defined for the compound of formula (I). This reaction (xi) is carried out in the presence of a complex of palladium (in oxidation state (0) or (II)) for example such as Pd(PPh₃)₄, PdCl₂(PPh₃)₂ or Pd₂(dba)₃ and optionally with addition of a ligand such as triphenyl arsine, trifurylphosphine or triphenylphosphine in a polar aprotic solvent such as DMF, dioxane or THF with heating to a temperature between 50 and 120°C.


10 In the case when group G, on compound (IXb), is a motif NR₅R₆, where R₅ and R₆ are as defined for the compound of formula (I), it is **route 1** that leads to formation of compound (X), which after a conventional stage of deprotection, as described previously, gives the compound of formula (I) according to the invention.

15 In the case when G is a (C₁-C₄)alkoxy group such as OEt, it is **route 2** that is followed, and compound (XI) is obtained by the Stille coupling of stage (xi), and the subsequent stages, (xii), (xiii) and of deprotection to give respectively the compounds of formula (XII) and (XIII) and (I) according to the invention, are identical respectively to stages (ix), (x) and of deprotection described previously.

20

25

Scheme 3



If necessary, certain reactive functions located on group R5, R6, R7 or R2 can be
5 protected in the course of these couplings by protecting groups, as described in
"Protective Groups in Organic Synthesis", Green et al., 2nd Edition.

In schemes 1, 2, 3, the starting compounds and the reagents, when their manner of preparation is not described, are commercially available or are described in the literature, or else can be prepared according to methods that are described in the literature or that are known by a person skilled in the art.

According to another of its aspects, the invention also relates to the compounds of formulae (VII), (VIII), (XI). These compounds are useful as synthesis intermediates of

the compounds of formula (I).

The following examples illustrate the preparation of certain compounds according to the invention. These examples are not limiting and their only purpose is to illustrate the present invention. The numbers of the compounds in the examples refer to those given in the following table, which presents the chemical structures and physical properties of some compounds according to the invention.

The following abbreviations and empirical formulae are used:

10	EtOAc	Ethyl acetate
	CDI	Carbonyldiimidazole
	DCM	Dichloromethane
	°C	degree Celsius
	DME	Dimethoxyethane
15	DMF	Dimethylformamide
	DMSO	Dimethyl sulphoxide
	EDC.HCl	N-[3-(dimethylamino)propyl-N'-ethyl carbodiimide hydrochloride
	BTUH	O-(-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate.
20	h	Hour(s)
	HCl	Hydrochloric acid
	LiOH	Lithium hydroxide
	Na ₂ CO ₃	Sodium carbonate
	NH ₄ Cl	Ammonium chloride
25	NaHCO ₃	Sodium hydrogen carbonate
	Na ₂ SO ₄	Sodium sulphate
	NaCl	Sodium chloride
	NaOH	Sodium hydroxide
	NH ₄ OH	Ammonium hydroxide
30	Na ₂ SO ₄	Sodium sulphate
	min.	minutes
	ml	millilitre

- 32 -

	P ₂ O ₅	diphosphorus pentoxide	
	SEM	2-Trimethylsilyl-ethoxymethyl	
	BTUT	N-[(1H-benzotriazol-1-yloxy)(dimethylamino) methylidene]-N-methylmethanaminium tetrafluoroborate	
5	TFA	Trifluoroacetic acid	
	THF	Tetrahydrofuran	
	RT	Room temperature	
	Tr	retention time	
	TOSMIC	Toulenesulphonylmethyl isocyanide	
10	Xphos	2-Dicyclohexylphosphinol-2',4',6'-triisopropylbiphenyl	

Equipment used:

- **Microwave apparatus:** Biotage, initiator

15

- **Analysis conditions:**

LC/UV/MS coupling conditions:

Instrument (Agilent): HPLC chain: Series 1100, Mass spectrometer MSD SL (Agilent),
Software: Chemstation version B.01.03 from Agilent

20 **LC/UV**

Column: Symmetry C18 3.5 µm (2.1 x 50 mm) (Waters), Column temp.: 25°C,
Post run: 5 min UV Detection: 220 nm. Injection volume: 2 µl of a solution at 0.5 mg/ml

Condition 1: pH 3 gradient 15 minutes

Eluents: A: H₂O + 0.005% TFA / B: CH₃CN + 0.005% TFA, Flow: 0.4 ml/min. Gradient: 0
25 to 10 min 0 to 100% B and from 10 to 15 min 100 B%

Condition 2: pH 3 gradient 30 minutes

Column: Symmetry C18 3.5 µm (2.1 x 50 mm) (Waters), Column temp.: 25°C, Eluents:
A: H₂O + 0.005% TFA / B: CH₃CN + 0.005% TFA, Flow: 0.4 ml/min. Gradient: 0 to 30
min 0 to 100% B and from 30 to 35 min 100 B%

30 Post run: 6 min. UV Detection: 220 nm. Injection volume: 2 µl of a solution at 0.5 mg/ml

Condition 3: pH 7 gradient 20 minutes

Column: X terra MS C18 3.5 µm (2.1x50 mm), Column temp.: 20°C Eluents: A H₂O +

- 33 -

AcNH₄ (5 mM) + 3% CH₃CN / B: CH₃CN. Gradient 0 to 20 min 0 to 100% of B. UV

Detection: 210 nm.

Condition GC Cl/CH₄+: ionization Cl/CH₄ +, 30 minutes

Column: Agilent HP-5MS 30 m x 250 µm film 0.25 µm thick. Temperature 250°C, Carrier

5 gas: Helium, constant flow 1.4 ml/min

MS:

ionization mode: Electrospray positive mode ESI+, mass range: 90-1500 uma

Spray Chamber Gas temp.: 350°C Drying gas (N₂): 10.0 l/min Neb. pressure: 30 psig

Vcap: 4000 V

10

The ¹H NMR spectra were obtained using NMR spectrometers Bruker 250, 300 or 400 MHz in DMSO-d₆, using the peak of DMSO-d₅ as reference. The chemical shifts δ are expressed in parts per million (ppm). The signals observed are expressed as follows: s = singlet; d = doublet; t = triplet; m = multiplet or large singlet; H = proton.

15

The melting points below 260°C were measured with a Kofler bench and melting points above 260°C were measured with a Buchi B-545 instrument.

The rotating powers were measured on a polarimeter of the type: Polarimeter Perkin-Elmer, energy 55µA.

20

Example 1: 2-{6-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-pyridin-3-yl}-N-pyridin-2-yl-acetamide (compound 2)

1.1 / 6-Chloro-2-(ethylamino)pyridine-3-carboxylic acid

25 A solution of 18.0 g (84.4 mmol) of 2,6-dichloronicotinic acid in 180 ml (3.45 mol) of a 70% solution of ethylamine in water is heated at 50°C for 10 hours. The excess amine is then evaporated under reduced pressure, then a 10% aqueous solution of acetic acid is added until the product is precipitated. The beige solid is filtered, rinsed with cold water and stove-dried. 10.5 g of the expected product is obtained. Yield = 62%. Melting point: 158-160°C. MH⁺: 201.1 (Tr: 7.7 min, condition 1).

30

1.2 / 6-Chloro-2-(ethylamino)pyridine-3-carboxylic fluoride

- 34 -

4.2 ml (52.3 mmol) of pyridine and 8.4 ml (99.6 mmol) of cyanuric fluoride are added successively to a suspension of 10.5 g (52.3 mmol) of the compound obtained at the end of stage 1.1 in dichloromethane (250 ml). The mixture is stirred for 3 hours at room temperature and then filtered. The solid is rinsed with dichloromethane (100 ml) and the filtrate is washed twice with ice water (60 ml). The organic phase is dried over Na₂SO₄ and then concentrated under reduced pressure. 10.44 g of product is obtained, in the form of an orange oil. Yield = 99%. The product is used without purification in the next stage.

10 1.3 / 1-(2-Trimethylsilyl-ethoxymethyl)-1H-imidazol-2-yl]-acetonitrile

Under inert atmosphere, 0.91 g (4.6 mmol) of TOSMIC in solution in anhydrous DME (4 ml) is added to 0.96 g (8.6 mmol) of potassium tert-butyrate in suspension in 4 ml of anhydrous DME at -35°C. The reaction mixture is cooled to -50°C then 1 g (4.4 mmol) of 1-(2-trimethylsilyl-ethoxymethyl)-1H-imidazole-2-carbaldehyde (Whitten JP, JOC 1986, 51 (10) 1891-1894) in solution in 4 ml of anhydrous DME is added dropwise, keeping the temperature below -45°C. The reaction mixture is stirred at this temperature for 30 min, then 11 ml of methanol is added, and the mixture is heated at 80°C for 15 minutes. The solvents are concentrated under reduced pressure, and the residue is taken up in a water/acetic acid mixture (13 ml / 0.5 ml), the aqueous phase is extracted with dichloromethane (3 X 100 ml), the organic phases are then washed with a saturated solution of NaHCO₃, then dried over Na₂SO₄. After filtration, the filtrate is concentrated under reduced pressure and the residue is purified by filtration on basic alumina (eluent: A/B = DCM/AcEt 0 to 50% of B), 0.71 g of compound is thus obtained in the form of a yellowish orange oil. Yield = 67%. MH⁺: 238 (Tr: 6.9 min, condition 1).
¹H NMR (300MHz, DMSO-d₆), δ (ppm): 7.31 (d, 1H); 6.89 (d, 1H); 5.34 (s, 2H); 4.19 (s, 2H); 3.46 (dd, 2H); 0.87 (dd, 2H); 0 (s, 9H).

1.4 / 2-Amino-7-chloro-1-ethyl-3-[1-(2-trimethylsilyl-ethoxymethyl)-1H-imidazol-2-yl]-1H-[1,8]naphthyridin-4-one

30 Under inert atmosphere, 2.4 g (20.5 mmol) of potassium tert-butyrate is added in portions to 4.9 g (20.5 mmol) of the compound obtained at the end of stage 1.3, in solution in anhydrous THF (50 ml) cooled to 0°C. After 45 minutes of stirring at room

- 35 -

temperature, the reaction mixture is cooled to 0°C, and 4.2 g (20.5 mmol) of the compound obtained at the end of stage 1.2, in solution in anhydrous THF (20 ml), is added dropwise. The mixture is stirred at room temperature for one hour, then 3.5 g (30.8 mmol) of potassium tert-butyrate is added and it is stirred for a further 2 hours.

- 5 500 ml of a saturated solution of ammonium chloride is added, and the medium is acidified to pH=4 by adding a solution (1N) of HCl. The aqueous phase is extracted with ethyl acetate (2x 500 ml). The organic phases are washed with a saturated solution of sodium chloride, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue is purified by silica gel flash chromatography (eluent: A/B = DCM/Methanol, from 0 to 5% of B). 6.1 g of compound is thus obtained in the form of a brown solid. Yield = 70%. Melting point = 90°C MH⁺: 419 (Tr: 6.6 min, condition 1).

¹H NMR (300MHz, DMSO-d₆), δ (ppm): 8.47 (d, 1H); 7.67 (s, 2H); 7.44 (d, 1H); 7.33 (d, 1H); 7.1 (d, 1H); 5.27 (s, 2H); 4.45 (q, 2H); 3.22 (dd, 2H); 1.28 (t, 3H); 0.63 (dd, 2H); -0.2 (s, 9H).

15

1.5 / 2-Amino-1-ethyl-3-[1-(2-trimethylsilylanyl-ethoxymethyl)-1H-imidazol-2-yl]-7-trimethylstannanyl-1H-[1,8]naphthyridin-4-one

- In a sealed tube, a solution of 2 g of the compound obtained at the end of stage 1.4 in 12 ml of dioxane is degassed with argon for 15 minutes, then 2.05 g (6.2 mmol) of hexamethylditin, 0.16 g (0.50 mmol) of triphenylarsine and 0.54 g (0.75 mmol) of bis(triphenylphosphine)dichloropalladium II are added successively under argon, then the tube is closed. The reaction mixture is heated for 4.5 h at 85°C, then concentrated under reduced pressure. The residue is purified directly on nitrile-grafted silica (eluent: A/B = (heptane/DCM 1/1)/AcEt from 0 to 100% of B), 2 g of compound is obtained in the form of a brown powder. Yield= 76%. Melting point = 76°C. MH⁺: 550 (Tr: 7.2 min, condition 1).

- ¹H NMR (400MHz, DMSO-d₆), δ (ppm): 8.28 (d, 1H, 7.5 Hz); 7.56 (d, 1H, 7.5 Hz); 7.53 (s, 2H); 7.32 (d, 1H, 1.3 Hz); 7.1(d, 1H, 1.3 Hz); 5.26 (s, 2H); 4.59 (q, 2H, 6.9 Hz); 3.18 (dd, 2H, 8.2- 8.04 Hz); 1.29 (t, 3H, 6.9 Hz); 0.6 (dd, 2H, 8.2- 8.04 Hz); 0.36 (t, 9H, 28 Hz); 0 (s, 9H).

30

1.6 / 2-(6-Chloro-pyridin-3-yl)-N-pyridin-2-yl-acetamide

- 36 -

Under inert atmosphere, 6.2 g (38.5 mmol) of N,N-carbodiimidazole is added to a suspension of 6 g (35 mmol) of 2-chloropyridylacetic acid in anhydrous THF (90 ml) at room temperature. The reaction mixture is stirred at this temperature for 2 hours, then 5.4 g (57.7 mmol) of 2-aminopyridine is added and the mixture is heated for 2 hours under reflux. 200 ml of dichloromethane is added to the reaction mixture, cooled beforehand to room temperature, the organic phase thus obtained is washed with a saturated solution of ammonium chloride, then with an aqueous solution of soda (1N), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue is purified by silica gel flash chromatography (eluent: A/B = dichloromethane / ethyl acetate 0% to 70% of B). 5.6 g of compound is obtained in the form of a white powder. Yield 65%. Melting point: 130°C. MH⁺: 248 (Tr: 5.6 min, condition 1).

¹H NMR (400MHz, DMSO-d₆), δ (ppm): 10.81 (s, 1H); 8.35 (d, 1H, 2.3 Hz); 8.33 (ddd, 1H, 0.9-1.9-4.9 Hz); 8.03 (d, 1H, 8.2 Hz); 7.82 (dd, 1H, 2.5-8.2Hz); 7.77 (ddd, 1H, 1.9-7.3, 8.2 Hz); 7.49 (d, 1H, 8.2Hz); 7.11 (ddd, 1H, 0.9-4.9-7.3Hz); 3.81(s, 2H).

1.7 / 2-(6-{7-Amino-8-ethyl-5-oxo-6-[1-(2-trimethylsilylanyl-ethoxymethyl)-1H-imidazol-2-yl]-5,8-dihydro-[1,8]naphthyridin-2-yl}-pyridin-3-yl)-N-pyridin-2-yl-acetamide

A solution of 0.365 g (1.5 mmol) of the compound obtained at the end of stage 1.6 and of 1.2 g (2.2 mmol) of the compound obtained at the end of stage 1.5 in anhydrous dioxane (7 ml) is degassed with argon for 10 minutes, then 0.170 g (0.23 mmol) of palladium II dichlorodi(triphenylphosphine) and 0.05 g (0.16 mmol) of triphenylarsine are added, the tube is sealed and the reaction mixture is heated at 100°C for 18 hours. The reaction mixture is diluted with 100 ml of dichloromethane, then the organic phase is washed with a 10% aqueous ammonia solution, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue is purified by silica gel flash chromatography (eluent: A/B = dichloromethane/methanol from 0% to 10% of B). 0.32 g of compound is obtained, in the form of a yellow powder. Yield: 37%. MH⁺: 597 (Tr: 6.1 min, condition 1)

1.8 / 2-{6-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-pyridin-3-yl}-N-pyridin-2-yl-acetamide hydrochloride (compound 2)

Under inert atmosphere, 1 ml of trifluoroacetic acid in solution in 0.5 ml of

- 37 -

dichloromethane is added dropwise to a suspension of 0.2 g (0.34 mmol) of the compound obtained at the end of stage 1.7 in suspension in dichloromethane (1 ml), cooled to 0°C. The reaction mixture is stirred at this temperature for 10 minutes, then at room temperature for 5 hours, then at 10°C overnight. The mixture is then poured into a solution of Na₂CO₃ (2N) (6 ml), previously cooled, the yellow precipitate formed is filtered and rinsed with water, then dried under vacuum over P₂O₅. The solid is purified by silica gel flash chromatography (eluent: A/B =dichloromethane/(methanol/1% NH₄OH), from 0% to 10% of B). 0.14 g of compound is obtained in the form of a yellow powder. Yield 87%. 0.1 ml of a concentrated HCl solution (35%) is added dropwise to 0.14 g (0.3 mmol) of this compound in suspension in methanol, the mixture is then stirred at room temperature for 45 minutes, then concentrated under reduced pressure. The solid is triturated in diethyl ether, filtered and dried under vacuum over P₂O₅. 0.15 g of hydrochloride compound is thus obtained in the form of beige powder. Yield: 86%. Melting point= 200°C. MH⁺ 467.2 (Tr: 5.49 min, condition 1)

¹H NMR (400MHz, DMSO-d₆), δ (ppm): 11.47 (s, 1H); 8.76 (d, 1H, 1.9Hz); 8.59 (d, 1H, 8 Hz); 8.52 (d, 1H, 8.2 Hz); 8.39 (d, 1H, 8 Hz); 8.36 (m, 1H); 8.08 (dd, 1H, 2-8.3 Hz); 8.03 (d, 1H, 8.3 Hz); 7.92 (m, 1H); 7.82 (s broad, 1H+ 1 HCl); 7.66 (s, 2H); 7.22 (m, 1H); 5.52 (s, 2 H+ 2 HCl); 4.75 (m, 2H); 4.0 (s, 2H); 1.37 (t, 3H, 6.85Hz).

Example 2: 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-cyclopropyl-morpholin-3-ylmethyl)-acetamide (compound 3)

2.1 / ethyl [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetate

A mixture of 9.5 g (33 mmol) of (4-iodo-phenyl)-ethyl acetate and of 9.2 g (36 mmol) of bispinacolatodiborane in solution in anhydrous dimethylsulphoxide (65 ml) is degassed with argon for 15 minutes, then 28 g (98 mmol) of potassium acetate and 1.34 g (1.6 mmol) of palladium dichloro(phosphinoferrocene) are added and the reaction mixture is heated at 55°C for 1.5 h under argon. The reaction mixture is diluted with 220 ml of ethyl acetate, then the organic phase is washed three times with water (200 ml), then dried over Na₂SO₄, and concentrated under reduced pressure. 11 g of compound is obtained in the form of a brown oil, but is used as it is in the next stage.

MH⁺: 291.2 (Tr: 9.4 min, condition 1)

2.2 / 4-{7-Amino-8-ethyl-5-oxo-6-[1-(2-trimethylsilyl-ethoxymethyl)-1H-imidazol-2-yl]-5,8-dihydro-[1,8]naphthyridin-2-yl}-phenyl-acetic acid

5 In a tube, a suspension of 0.7 g (2.4 mmol) of the compound obtained at the end of stage 2.1, 0.5 g (1.2 mmol) of the compound obtained at the end of stage 1.4 and 3.3 ml of a saturated solution of hydrogen carbonate in 7 ml of a mixture of DME/ethanol (2/1), is degassed with argon for 10 minutes, then 0.08 g (0.07 mmol) of palladium tetrakis(triphenylphosphine) is added and the tube is sealed. The reaction mixture is
10 heated at 170°C for 15 minutes in a microwave (Biotage *initiator*). The reaction mixture is then taken up in water, and acidified by adding 1N HCl solution. The solid is collected by filtration, rinsed with water and then dried over P₂O₅ under vacuum. 0.87 g of product is obtained in the form of a mixture of acid and ester. This mixture is used directly in the next stage.

15 0.1 g (2.4 mmol) of lithium hydroxide monohydrate is added to 0.87 g of the mixture of acid and ester obtained at the end of the preceding stage, in suspension in a solvent mixture THF/water/methanol (1/1/1). The reaction mixture is heated at 70°C for 5 hours. 3.5 ml of water is added to the reaction mixture cooled to room temperature, followed by addition of HCl solution (1N) to pH 1. The solid is collected by filtration,
20 rinsed with dichloromethane, then dried over P₂O₅ under vacuum. 0.4 g of product is thus isolated, without any other purification, in the form of grey powder. Yield: 62% for the two stages. Melting point: 220°C. MH⁺: 467.2 (Tr: 5.49 min, condition 1).

¹H NMR (400MHz, DMSO-d₆), δ (ppm): 14.42 (s, 1H); 12.46 (s, 1H); 8.46 (d, 1H, 7.2 Hz); 8.19 (d, 2H, 7.2 Hz); 8.02 (d, 1H, 7.2 Hz); 7.89 (s, 1H); 7.83 (s, 1H); 7.58 (s, 2H);
25 7.47 (d, 2H, 7.2 Hz); 5.35 (s, 2H); 4.68 (m, 2H); 3.7(s, 2H); 3.42 (m, 2H); 1.37(m, 3H); 0.77 (m, 2H); -0.11(s, 9H).

2.3/ 4-Cyclopropyl-morpholine-3-carboxamide

2.9 g of molecular sieve 3A, 4.3 g (72 mmol) of acetic acid, 7.6 g (43.2 mmol) of
30 2(1-ethoxy-cyclopropyl)oxy]trimethylsilane and 4.4 g (31.7 mmol) of sodium cyanoborohydride are added successively to 1.2 g (7.2 mmol) of morpholine-3-carboxylic acid amide hydrochloride (WO2005026156 Hennequin L.F.A. et al.) in

solution in methanol (36 ml). The reaction mixture is heated at 70°C for 3.5 hours, then cooled to room temperature and filtered. The filtrate is concentrated under reduced pressure, then the residue is taken up in dichloromethane (200 ml) and washed 3 times with an aqueous solution of NaOH (1N) (100 ml). The organic phase is dried over Na₂SO₄, filtered and then concentrated under reduced pressure. 0.58 g of product is obtained, in the form of a white powder. Yield 47%. Melting point 116°C. MH⁺: 171 (Tr: 1.03 min, condition 2).

¹H NMR (250MHz, DMSO-d₆), δ (ppm): 7.33 (s, 1H); 6.98 (s, 1H); 3.67-3.43 (m broad, 4H); 2.97 (dd, 2H, 7.3 – 3.6 Hz); 2.35 (ddd, 1H, 11.7- 8.3 – 3.4 Hz); 1.89(ddd, 1H, 10.3- 6.6- 3.6 Hz); 0.56-0.22 (m broad, 4H).

2.4/ 1-(4-cyclopropylmorpholin-3-yl)methanamine hydrochloride

Under inert atmosphere, 13.6 ml (13.6 mmol) of a solution (1N) of triborohydride complexed with tetrahydrofuran in THF is added dropwise to a solution of 0.58 g (3.4 mmol) of the compound obtained at the end of stage 2.3, in anhydrous THF, cooled to 0°C. The reaction mixture is heated at 70°C for 3h. 15 ml of a solution (1N) of HCl is added to the reaction mixture cooled to room temperature, after 30 min of stirring the aqueous phase is decanted and extracted twice with ether (15 ml) then basified by adding soda solution (1N). The aqueous phase is then extracted with ethyl acetate 4 times (20 ml) and with dichloromethane 4 times (20 ml). The combined organic phases are dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue is taken up in methanol (4 ml) and 3.4 ml of a solution of HCl (1N) in ether is added, the solution is stirred for 30 minutes then 5 ml of ether is added, the solid formed is collected by filtration and dried under vacuum over P₂O₅. 0.51 g of product is obtained, in the form of a white powder. Yield 78%. MH⁺: 157 (Tr: 0.4 min, condition 2).

¹H NMR (400MHz, DMSO-d₆), δ (ppm): 11.67(s, 1H); 8.07 (m, 2H); 4.09 (m, 1H); 3.94 (m, 1H); 3.74 (m, 2H); 3.54 (m, 2H); 3.36 (m, 1H); 3.2 (m, 1H); 2.99 (m, 1H); 1.25 (m, 1H); 1.09-0.72 (m, 4H).

30 2.5/ 2-{4-[7-amino-8-ethyl-5-oxo-6-(1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl)-5,8-dihydro-1,8-naphthyridin-2-yl]phenyl}-N-[(4-cyclopropylmorpholin-3-yl)methyl]acetamide

- 40 -

Under inert atmosphere, 0.4 ml (2.3 mmol) of diisopropyl ethyl amine is added to 0.4 g (0.8 mmol) of the compound obtained at the end of stage 2.2, in suspension in DMF (8 ml); after dissolution, the reaction mixture is cooled to 0°C then a solution, in DMF (2 ml), of 0.18 g (0.94 mmol) of the compound obtained at the end of stage 2.4 and of 0.2 ml (1.2 mmol) of diisopropyl ethyl amine is added, followed by addition of 0.275 g (0.86 mmol) of BTUT. The reaction mixture is stirred at room temperature for 3 hours, then concentrated to dryness. The residue is purified directly by silica gel flash chromatography (eluent: A/B = dichloromethane/methanol (1% NH₄OH) gradient from 0 to 10% of B). 0.34 g of product is obtained in the form of a yellow powder. Yield: 65%.
Melting point: 116°C.
MH⁺: 657 (Tr: 5.51 min, condition 1)

2.6 / 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-cyclopropyl-morpholin-3-ylmethyl)-acetamide
hydrochloride (compound 3)

1.4 ml (19 mmol) of trifluoroacetic acid in solution in 0.4 ml of dichloromethane is added dropwise to 0.3 g (0.47 mmol) of the compound obtained at the end of stage 2.5, in solution in 0.4 ml dichloromethane, cooled to -10°C, then the reaction mixture is stirred at 5°C overnight and then poured into a solution of Na₂CO₃ (2M) (10 ml) in the cold (ice bath). The yellow precipitate formed is collected by filtration and rinsed with water, and then dried over P₂O₅ under vacuum. The 0.18 g of solid is taken up in 2 ml of methanol and 70 µl of a 36% solution of HCl is added, the mixture is stirred for one hour at room temperature, then concentrated under vacuum. The residue is purified by flash chromatography on a C8 reverse phase column (eluent: water HCl (N/ 1000). 0.034 g of product is obtained in the form of a yellow powder. Yield = 16%. Melting point: 210°C. MH⁺: 528.2 (Tr: 4.78 min, condition 1).

¹H NMR (400MHz, DMSO-d₆), δ (ppm): 11.29 (s, 1H); 8.52 (d, 1H, 8.2 Hz); 8.48 (s, 1H exchangeable); 8.18 (d, 2H + 1H exchangeable, 8.3 Hz); 7.99 (d, 1H + 1H exchangeable, 8.2 Hz); 7.54 (s, 2H); 7.48 (d, 2H, 8.3 Hz); 4.7 (q broad, 2H, 7 Hz); 3.91 (m, 3H); 3.73 (m, 1H); 3.58 (s, 3H); 3.47 (m, 2H); 3.34 (m, 2H); 2.93 (m, 1H); 1.36 (t, 3H, 7Hz); 1.25 (m, 1H); 0.95 (m, 2H); 0.81(m, 1H).

Example 3: 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-propionamide (compound 47)

3.1/ ethyl 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propanoate

Same procedure as that described in example 2, stage 2.1, starting from 0.6 g (2 mmol) of ethyl 2-(4-iodophenyl)propanoate in solution in anhydrous DMSO (4 ml), 0.57 g (2.2 mmol) of bispinacolatodiborane, 1.7 g (6 mmol) of potassium acetate and 83 mg (0.1 mmol) of palladium dichloro(phosphinoferrocene). 0.9 g of compound is obtained in the form of a brown oil, used as it is in the next stage. MH^+ : 305 (Tr: 9.9 min, condition 1)

3.2/ 2-{4-[7-amino-8-ethyl-5-oxo-6-(1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl)-5,8-dihydro-1,8-naphthyridin-2-yl]phenyl}propanoic acid

Same procedure as that described in example 2, stage 2.2, starting from 0.57 g (1.4 mmol) of the compound obtained at the end of stage 3.1, 0.82 g (2.7 mmol) of the compound obtained at the end of stage 1.4, 94 mg (0.08 mmol) of palladium tetrakis(triphenylphosphine), 4 ml of a saturated solution of hydrogen carbonate in a mixture of DME/ethanol (2/1) (7 ml), 1.1 g of product is obtained in the form of a mixture of acid and ester. This mixture is used directly in the next stage, in the presence of 0.16 g (3.8 mmol) of lithium hydroxide monohydrate suspension in a solvent mixture THF/water/methanol (1/1/1) (10 ml). 0.4 g of product is obtained in the form of brown powder. Yield: 39% for the two stages. Melting point: 248°C. MH^+ 534.1 (Tr: 6.5 min, condition 1)

3.3/ 2-{4-[7-amino-8-ethyl-5-oxo-6-(1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl)-5,8-dihydro-1,8-naphthyridin-2-yl]phenyl}-N-(pyridin-4-ylmethyl)propanamide

Same procedure as that described in example 2, stage 2.5, starting from 0.3 g (0.56 mmol) of the compound obtained at the end of stage 3.2, 0.25 g (2.25 mmol) of 1-(pyridin-4-yl)methanamine, 0.36 g (1.1 mmol) of BTUT and 0.14 g (1.1 mmol) of diisopropylethylamine in anhydrous DMF (5 ml), 0.29 g of product is obtained in the form of yellow powder. Yield: 82%. Melting point: 140°C. MH^+ : 624 (Tr: 5.66 min, condition 1).

3.4/

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-propionamide (compound 47)

Same procedure as that described in example 2, stage 2.6, starting from 0.26 g (0.42 mmol) of the compound obtained at the end of stage 3.3 in solution in 1.2 ml of dichloromethane, 1.3 ml (17 mmol) of trifluoroacetic acid in solution in 0.5 ml of dichloromethane. 0.051 g of product is obtained in the form of a yellow powder. Yield = 24%. Melting point: 186°C. MH⁺: 494.2 (Tr: 5.05 min, condition 1).

¹H NMR (400MHz, DMSO-d₆), δ (ppm): 13.20 (s, 1H); 11.51 (s, 1H); 8.62 (m, 2H); 8.45 (dd, 2H, 4.5, 1.5 Hz); 8.29 (d, 2H, 8.2 Hz); 8.02 (s broad, 1H exchangeable); 7.97 (d, 1H, 8.2 Hz); 7.53 (d, 2H, 8.2 Hz); 7.16 (m, 3H); 7.04 (m, 1H); 4.72 (m, 2H); 4.29 (d, 2H, 6 Hz); 3.81 (q, 1H, 7 Hz); 1.45 (d, 3H, 7.1 Hz); 1.38 (t, 3H, 7 Hz).

Example 4: 4-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-butamide (compound 49)

4.1/ 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]butanoic acid

Same procedure as that described in example 2, stage 2.1, starting from 0.3 g (1 mmol) of 4-(4-iodophenyl)butanoic acid in solution in anhydrous DMSO (2 ml), 0.29 g (1.1 mmol) of bispinacolatodiborane, 0.3 g (3.1 mmol) of potassium acetate and 42 mg (0.05 mmol) of palladium dichloro(phosphinoferrocene). 0.21 g of compound is obtained in the form of a brown oil, used as it is in the next stage. MH⁺: 291 (Tr: 8.35 min, condition 1)

4.2 / 4-[4-(7-amino-8-ethyl-5-oxo-6-{1-[2-(trimethylsilyl)ethoxy]-1H-imidazol-2-yl]-5,8-dihydro-1,8-naphthyridin-2-yl)phenyl]butanoic acid

Same procedure as that described in example 2, stage 2.2, from 0.17 g (0.57 mmol) of the compound obtained at the end of stage 4.1, 0.18 g (0.44 mmol) of the compound obtained at the end of stage 1.4, 25 mg (0.02 mmol) of palladium tetrakis(triphenylphosphine), 1.2 ml of a saturated solution of hydrogen carbonate in a mixture of DME/ethanol (2/1) (3 ml), 0.25 g of product is obtained in the form of a brown oil used as it is in the next stage. MH⁺: 548 (Tr: 6.5 min, condition 1)

4.3/ 4-[4-(7-amino-8-ethyl-5-oxo-6-{1-[2-(trimethylsilyl)ethoxy]-1H-imidazol-2-yl]-5,8-dihydro-1,8-naphthyridin-2-yl}phenyl)-N-(pyridin-4-ylmethyl)butanamide

Same procedure as that described in example 2, stage 2.5, starting from 0.5 g (0.46 mmol) of the compound obtained at the end of stage 4.2, 0.2 g (1.8 mmol) of 1-(pyridin-4-yl)methanamine, 0.3 g (0.9 mmol) of BTUT and 0.12 g (0.9 mmol) of diisopropylethylamine in anhydrous DMF (5 ml), 0.1 g of product is obtained in the form of beige powder. Yield: 34%. Melting point: 223°C. MH⁺: 638 (Tr: 5.75 min, condition 1).

10 4.4/ 4-[4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl]-N-pyridin-4-ylmethyl-butamide (compound 49)

Same procedure as that described in example 2, stage 2.6, starting from 0.095 g (0.15 mmol) of the compound obtained at the end of stage 4.3 in solution in 0.5 ml of dichloromethane, 0.44 ml (6 mmol) of trifluoroacetic acid in solution in 0.3 ml of dichloromethane. 0.045 g of product is obtained in the form of a yellow powder. Yield = 60%. Melting point: 240°C. MH⁺: 508.2 (Tr: 4.97 min, condition 1).

¹H NMR (400MHz, DMSO-d₆), δ (ppm): 13.21 (s, 1H); 11.48 (s, 1H); 8.61 (d, 1H, 8 Hz); 8.49 (d, 2H, 4.5 Hz); 8.44 (t, 1H, 6 Hz); 8.45 (s broad, 1H exchangeable); 8.17 (d, 2H, 8.1 Hz); 7.97 (d, 1H, 8.1 Hz); 7.39 (t, 2H, 8.1 Hz); 7.24 (d, 1H, 4.8Hz); 7.15 (s, 1H); 7.03 (s, 1H); 4.72 (m, 2H); 4.30 (d, 2H, 5.8 Hz); 3.81 (q, 1H, 7 Hz); 2.68 (t, 2H, 7.5 Hz); 2.24 (t, 2H, 7.3 Hz); 1.92 (m, 2H); 1.38 (t, 3H, 7 Hz).

Example 5: 2-[4-[7-Amino-8-ethyl-6-(4-methyl-1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl]-N-pyridin-4-ylmethyl-acetamide
(compound 50)

5.1/ [1-(2-Trimethylsilylanyl-ethoxymethyl)-1H-(4-methyl-1H-imidazol-2-yl)acetonitrile

Same procedure as that described in example 1, stage 1.3, starting from 4.6 g (19 mmol) of [1-(2-Trimethylsilylanyl-ethoxymethyl)-1H-(4-methyl-1H-imidazol-2-yl)carbaldehyde, 4 g (20.3 mmol) of TOSMIC and 4.3 g of potassium tert-butyrate in solution in anhydrous DME (32 ml). 2.2 g of compound is obtained in the form of a

yellow oil as 70/30 mixture of τ and π regioisomers (Yield 45%. MH^+ : 252 (Tr: 6.38 and 6.55 min, condition 1)

5.2 / 2-amino-7-chloro-1-ethyl-3-(4-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl)-1,8-naphthyridin-4(1H)-one

Same procedure as that described in example 1, stage 1.4, starting from 1 g (4 mmol) of the compound obtained at the end of stage 5.1, 0.8 g (4 mmol) of the compound obtained at the end of stage 1.2 and 1.15 g (10 mmol) of potassium tert-butylate in solution in anhydrous THF (13 ml). 0.42 g of product is obtained in the form of a beige powder. Yield 24%. Melting point: 120°C. MH^+ : 435 (Tr: 10.5 and 10.6 min, condition 1)

5.3/ {4-[7-amino-8-ethyl-6-(4-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl)-5-oxo-5,8-dihydro-1,8-naphthyridin-2-yl]phenyl}acetic acid

Same procedure as that described in example 2, stage 2.2, starting from 0.42 g (1 mmol) of the compound obtained at the end of stage 5.2, 0.84 g (2.9 mmol) of the compound obtained at the end of stage 2.1, 67 mg (0.06 mmol) of palladium tetrakis(triphenylphosphine), 1.2 ml of a saturated solution of hydrogen carbonate in a solvent mixture DME/EtOH (2/1) (7 ml). 0.69 g of product is obtained in the form of a mixture of acid and ester. This mixture is used directly in the next stage, in the presence of 0.12 g (3 mmol) of lithium hydroxide monohydrate suspension in a solvent mixture THF/water/methanol (1/1/1) (7 ml). 0.67 g of product is obtained in the form of brown powder used without purification. MH^+ : 534 (Tr: 4.38 min, condition 1).

5.4/ 2-{4-[7-amino-8-ethyl-6-(4-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl)-5-oxo-5,8-dihydro-1,8-naphthyridin-2-yl]phenyl}-N-(pyridin-4-ylmethyl)acetamide

Same procedure as that described in example 2, stage 2.5, starting from 0.67 g (1.2 mmol) of the compound obtained at the end of stage 5.3, 0.55 g (5 mmol) of 1-(pyridin-4-yl)methanamine, 0.8 g (2.5 mmol) of BTUT and 0.32 g (2.4 mmol) of diisopropylethylamine in anhydrous DMF (12 ml), 0.22 g of product is obtained in the form of yellow powder. Yield: 28%. MH^+ : 624 (Tr: 5.6 min, condition 1).

5.5/ 2-{4-[7-Amino-8-ethyl-6-(4-methyl-1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide salt of TFA (compound 50)

5 Same procedure as that described in example 2, stage 2.6, starting from 0.22 g (0.36 mmol) of the compound obtained at the end of stage 5.4 in solution in 0.5 ml of dichloromethane, 1.6 ml (14 mmol) of trifluoroacetic acid in solution in 0.5 ml of dichloromethane, purification by HPLC. 0.124 g of product, in the form of salt of trifluoroacetic acid, is obtained in the form of a yellow powder. Yield = 60%. Melting
10 point: 144°C. MH⁺: 494 (Tr: 4.54 min, condition 1).

¹H NMR (400MHz, DMSO-d₆), δ (ppm): 8.83 (t, 1H, 5.9 Hz); 8.68 (d, 2H, 5.2 Hz); 8.52 (d, 1H, 8.1 Hz); 8.19 (d, 2H, 8.3 Hz); 8.09 (s broad, 1H exchangeable); 8.0 (d, 1H, 8.2 Hz); 7.6 (d, 2H, 5.9 Hz); 7.5 (d, 2H, 8.3 Hz); 7.2 (s, 1H); 4.7 (m, 2H); 5.4-4 (s broad, 2H exchangeable); 4.46 (d, 2H, 6 Hz); 3.66 (s, 2H); 2.3 (s, 3H); 1.4 (t, 3H, 7 Hz)

15

Example 6: 2-{4-[7-Amino-8-cyclopropylmethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide (compound 51)

20 6.1/ 6-chloro-2-[(cyclopropylmethyl)amino]pyridine-3-carboxylic acid

In a sealable tube, 3 g (42 mmol) of cyclopropylmethylamine is added to 3 g (14 mmol) of 2,6-dichloronitric acid in solution in *tert*-butanol (14 ml), the tube is sealed and heated at 170°C for 30 minutes in a Biotage Initiator microwave. The reaction mixture is cooled to room temperature, diluted in dichloromethane (100 ml) and washed
25 with a 10% aqueous solution of acetic acid (12 ml). The organic phase is dried over Na₂SO₄, filtered, concentrated and dried under vacuum. 3.4 g of product is obtained in the form of an orange oil. Yield is quantitative. MH⁺: 227 (Tr: 4.54 min, condition 1)

6.2 / 6-chloro-2-[(cyclopropylmethyl)amino]pyridine-3-carbonyl fluoride

30 Same procedure as that described in example 1, stage 1.2, starting from 0.43 g (2 mmol) of the compound obtained at the end of stage 6.1 in solution in 4 ml of

Same procedure as that described in example 1, stage 1.4, starting from 0.43 g (2 mmol) of the compound obtained at the end of stage 6.2, 0.5 g (2 mmol) of the compound obtained at the end of stage 1.3 in solution in 6 ml of anhydrous THF and 0.55 g (5 mmol) of potassium tert-butyrate and 0.4 g (3.8 mmol) of triethylamine. 0.5 g of product is obtained in the form of a brown powder. Yield = 60%. Melting point: 70°C. MH^+ : 447 (Tr: 6.68 min, condition 1).

Same procedure as that described in example 2, stage 2.2, starting from 0.44 g (1 mmol) of the compound obtained at the end of stage 6.3, 1 g (3.5 mmol) of the compound obtained at the end of stage 2.1, 70 mg (0.06 mmol) of palladium tetrakis(triphenyl)phosphine, 2.8 ml of a saturated solution of hydrogen carbonate in a solvent mixture DME/EtOH (2/1) (8 ml). 0.8 g of product is obtained in the form of a mixture of acid and ester. This mixture is used directly in the next stage, in the presence of 0.15 g (3.6 mmol) of lithium hydroxide monohydrate in suspension in a solvent mixture THF/water/methanol (1/1/1) (9 ml). 0.91 g of product is obtained in the form of brown powder, used without purification in the next stage. MH^+ : 546 (Tr: 4.39 min, condition 1).

Same procedure as that described in example 2, stage 2.5, starting from 0.9 g (1.7 mmol) of the compound obtained at the end of stage 6.4, 0.73 g (6.7 mmol) of 1-

(pyridin-4-yl)methanamine, 1.1 g (3.3 mmol) of BTUT and 0.43 g (3.3 mmol) of diisopropylethylamine in anhydrous DMF (17 ml), 0.3 g of product is obtained in the form of beige powder. Yield: 28%. Melting point: 114°C. MH⁺: 635 (Tr: 5.6 min, condition 1).

5 6.6/ 2-{4-[7-Amino-8-cyclopropylmethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide salt of TFA (compound 51)

Same procedure as that described in example 2, stage 2.6, starting from 0.28 g (0.45 mmol) of the compound obtained at the end of stage 6.5 in solution in 1.5 ml of dichloromethane, 1.3 ml (18 mmol) of trifluoroacetic acid in solution in 0.8 ml of dichloromethane. 0.2 g of product is obtained in the form of a yellow powder. Yield = 60%. Melting point: 118°C. MH⁺: 506 (Tr: 4.96 min, condition 1).

¹H NMR (400MHz, DMSO-d₆), δ (ppm): 8.85 (t, 1H, 5.7 Hz); 8.7 (d, 2H, 5.8 Hz); 8.58 (s broad, 1H exchangeable); 8.56 (d, 1H, 8.1 Hz); 8.16 (d, 2H, 8.1 Hz); 8.0 (d, 1H, 8.2 Hz); 7.64 (d, 2H, 5.8 Hz); 7.50 (d, 2H, 8.2 Hz); 7.4 (s, 2H); 4.7 (m, 2H); 5.4-4.0 (s broad, 2H exchangeable); 4.50 (d, 2H, 5.8 Hz); 3.67 (s, 2H); 1.4 (m, 1H); 0.6 (m, 2H); 0.5 (m, 2H).

Example 7: 2-{5-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-pyridin-2-yl}-N-pyridin-4-ylmethyl-acetamide (compound 53)

7.1/ 2-(5-bromopyridin-2-yl)-N-(pyridin-4-ylmethyl)acetamide

Same procedure as that described in example 2, stage 2.5, starting from 0.33 g (1.5 mmol) of (5-bromo-pyridin-2-yl)-acetic acid (a synthesis of which is described in Tetrahedron, 1997, 53(24) 8257-8268 Gurnos J. et al.), 0.67 g (6.1 mmol) of 1-(pyridin-4-yl)methanamine, 1 g (3 mmol) of BTUT and 0.4 g (3 mmol) of diisopropylethylamine in anhydrous DMF (15 ml), 0.59 g of product is obtained in the form of beige powder, used without purification in the next stage. MH⁺: 307 (Tr: 2.92 min, condition 1).

7.2/ 2-{5-[7-amino-8-ethyl-5-oxo-6-(1-{2-(trimethylsilyl)ethoxy}methyl)-1H-imidazol-2-yl]-5,8-dihydro-1,8-naphthyridin-2-yl}pyridin-2-yl}-N-(pyridin-4-ylmethyl)acetamide

- 48 -

Same procedure as that described in example 1, stage 1.7, starting from 0.58 g (1.9 mmol) of the compound obtained at the end of stage 7.1, 1.2 g (2.3 mmol) of the compound obtained at the end of stage 1.5, 220 mg (0.3 mmol) of palladium II dichlorodi(triphenylphosphine) and 65 mg (0.21 mmol) of triphenylarsine in solution in 9 ml of anhydrous dioxane. 0.38 g of compound is obtained, in the form of a yellow powder. Yield: 32%. MH⁺: 611 (Tr: 5.43 min, condition 1).

7.3/

2-{5-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-pyridin-2-yl}-N-pyridin-4-ylmethyl-acetamide (compound 53)

Same procedure as that described in example 1, stage 1.8, starting from 0.36 g (0.6 mmol) of the compound obtained at the end of stage 7.2 in solution in 1.8 ml of dichloromethane, 1.8 ml (24 mmol) of trifluoroacetic acid in solution in 1 ml of dichloromethane. 0.314 g of product is obtained in the form of a yellow powder. Yield = 78%. Melting point: 120°C. MH⁺: 481 (Tr: 4.32 min, condition 1).

¹H NMR (400MHz, DMSO-d₆), δ (ppm): 9.38 (d, 1H, 2.3 Hz); 8.93 (t, 1H, 6 Hz); 8.77 (d, 2H, 6.3 Hz); 8.68 (s broad, 1H exchangeable); 8.62 (d, 1H, 8Hz); 8.57 (dd, 1H, 8.2, 2.4 Hz); 8.1 (d, 1H, 8 Hz); 7.77 (d, 2H, 6 Hz); 7.60 (d, 1H, 8.2Hz); 7.41 (s, 2H); 4.71 (m, 2H); 5.4-4 (s broad, 2H exchangeable); 4.54 (d, 2H, 6 Hz); 3.90 (s, 2H); 1.38 (t, 3H, 7 Hz).

Example 8: 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-2-fluoro-phenyl}-N-(1-ethyl-pyrrolidin-2-ylmethyl)-acetamide (compound 56)

8.1/ (4-bromo-2-fluorophenyl)acetic acid

0.09 g of lithium hydroxide monohydrate is added to 0.37 g (1.4 mmol) of ethyl ester of (4-bromo-2-fluorophenyl)acetic acid in solution in 8 ml of a solvent mixture THF/methanol/water (1/1/1), and the reaction mixture is stirred for 3h at room temperature. The reaction mixture is acidified with 1N HCl solution, then extracted with dichloromethane (20 ml). The organic phases are combined, dried over Na₂SO₄, filtered and concentrated under reduced pressure. 0.3 g of product is obtained in the form of gum and is used without purification in the next stage. Yield 91%.

8.2/ (4-bromo-2-fluorophenyl)acetyl chloride

0.3 g (2.4 mmol) of oxalyl chloride is added to 0.28 g (1.2 mmol) of the compound obtained at the end of stage 8.1 in solution in 7 ml of 1,2-dichloroethane. The
5 reaction mixture is stirred at room temperature for 1.5 h and then concentrated under reduced pressure. 0.322 g of compound is obtained in the form of an oil and is used without purification in the next stage.

8.3/ 2-(4-bromo-2-fluorophenyl)-N-[(1-ethylpyrrolidin-2-yl)methyl]acetamide

10 0.15 g (1.2 mmol) of 1-(1-ethylpyrrolidin-2-yl)methanamine is added to 0.3 g (1.2 mmol) of the compound obtained at the end of stage 8.2 in solution in 8 ml of dichloromethane cooled by an ice bath and under inert atmosphere, and it is stirred for a further 4h. The reaction mixture is diluted with 20 ml of dichloromethane and washed with 20 ml of water, then the organic phase is dried over Na₂SO₄, filtered and
15 concentrated under reduced pressure. The residue is then purified by silica gel flash chromatography (eluent: A/B = dichloromethane/methanol (1% NH₄OH) gradient from 0 to 10% of B). 0.2 g of product is obtained in the form of a beige powder. Yield: 50%. MH⁺ 343 (Tr: 4.94 min, condition 1).

20 8.4 / 2-{4-[7-amino-8-ethyl-5-oxo-6-(1-{2-(trimethylsilyl)ethoxy)methyl}-1H-imidazol-2-yl]-5,8-dihydro-1,8-naphthyridin-2-yl]-2-fluorophenyl}-N-[(1-ethylpyrrolidin-2-yl)methyl]acetamide

Same procedure as that described in example 1, stage 1.7, starting from 0.074 g (0.22 mmol) of the compound obtained at the end of stage 8.3, 0.15 g (0.3 mmol) of the
25 compound obtained at the end of stage 1.5, 24 mg (0.03 mmol) of palladium II dichlorodi(triphenylphosphine) and 8 mg (0.02 mmol) of triphenylarsine in solution in 1 ml of anhydrous dioxane. 0.063 g of compound is obtained, in the form of a yellow powder. Yield: 45%. MH⁺: 648 (Tr: 5.31 min, condition 1).

30 8.5/ 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-2-fluoro-phenyl}-N-(1-ethyl-pyrrolidin-2-ylmethyl)-acetamide
(compound 56)

- 50 -

Same procedure as that described in example 2, stage 2.6, starting from 0.055 g (0.08 mmol) of the compound obtained at the end of stage 8.4 in solution in 0.25 ml of dichloromethane, 0.25 ml (3.4 mmol) of trifluoroacetic acid in solution in 0.1 ml of dichloromethane. 0.017 g of product is obtained in the form of a yellow powder. Yield = 39%. Melting point: 100°C. MH⁺: 518.3 (Tr: 4.71 min, condition 1).

¹H NMR (400MHz, DMSO-d₆), δ (ppm): 9.15 (s, 1H); 8.62 (d, 1H, 8.1 Hz); 8.50 (t, 1H, 5.7 Hz); 8.07-8.0 (m, 3H); 7.54 (t, 1H, 8Hz); 7.24 (s, 2H); 4.70 (m, 2H); 3.92-3.32 (m, 6H + 3H exchangeable); 3.08 (m, 2H); 2.13 (m, 1H); 1.97 (m, 1H); 1.86 (m, 1H); 1.74 (m, 1H); 1.38 (t, 3H, 7 Hz); 1.22 (t, 3H, 7.2Hz).

10

Compounds 1, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 48 and 55 were synthesized following the synthesis route described in example 2; compound 9 following the synthesis route described in example 1, and compounds 52 and 54 were synthesized following the synthesis route described in example 6.

15

The following table presents chemical structures and physical properties of some examples of the compounds according to the invention.

In this table:


20

- in the "salt" column:

- " - " represents a compound in the form of free base, whereas
- "HCl" or "TFA" signify, respectively, a compound in the form of hydrochloride or of salt of trifluoroacetic acid.





- Me, Et, represent methyl and ethyl groups respectively.





25









where **R6** represents $-(\text{CH}_2)_n-\text{L}$





No.	m	n	R1	R3	R4	R5	L	R2	v	w	Y	Z	Salt	LCMS MH ⁺
-----	---	---	----	----	----	----	---	----	---	---	---	---	------	-------------------------





No.	m	n	R1	R3	R4	R5	L	R2	v	w	Y	Z	Salt	LCMS MH ⁺
1	1	0	H	H	H	H		Et	CH	CH	CH	CH	HCl	466
2	1	0	H	H	H	H		Et	CH	CH	N	CH	HCl	467.1
3	1	1	H	H	H	H		Et	CH	CH	CH	CH	HCl	528.2
4	1	1	H	H	H	H		Et	CH	CH	CH	CH	HCl	530





No.	m	n	R1	R3	R4	R5	L	R2	v	w	Y	Z	Salt	LCMS MH ⁺
5	1	0	H	H	H			Et	CH	CH	CH	CH	TFA	526.31
6	1	2	H	H	H	H		Et	CH	CH	CH	CH	TFA	494.24
7	1	2	H	H	H	Me		Et	CH	CH	CH	CH	TFA	508.25
8	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	486.18





No.	m	n	R1	R3	R4	R5	L	R2	v	w	Y	Z	Salt	LCMS MH ⁺
9	1	2	H	Me	H	H		Et	CH	CCH ₃	CH	CH	-	514.26
10	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	480.23
11	1	1	H	H	H	H		Et	CH	CH	CH	CH	TFA	497.24
12	1	1	H	H	H	H		Et	CH	CH	CH	CH	TFA	486.25




No.	m	n	R1	R3	R4	R5	L	R2	v	w	Y	Z	Salt	LCMS MH ⁺
13	1	1	H	H	H	H		Et	CH	CH	CH	CH	TFA	486.24
14	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	487.19
15	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	473.19
16	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	470.22




No.	m	n	R1	R3	R4	R5	L	R2	v	w	Y	Z	Salt	LCMS MH ⁺
17	1	2	H	H	H	H		Et	CH	CH	CH	CH	TFA	500.3
18	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	486.25
19	1	1	H	H	H	H		Et	CH	CH	CH	CH	TFA	480.21
20	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	513.2





No.	m	n	R1	R3	R4	R5	L	R2	v	w	Y	Z	Salt	LCMS MH ⁺
21	1	2	H	H	H	H		Et	CH	CH	CH	CH	TFA	494.28
22	1	1	H	H	H	H		Et	CH	CH	CH	CH	TFA	497.25
23	1	1	H	H	H	H		Et	CH	CH	CH	CH	TFA	483.25
24	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	467.22




No.	m	n	R1	R3	R4	R5	L	R2	v	w	Y	Z	Salt	LCMS MH ⁺
25	1	2	H	H	H	H		Et	CH	CH	CH	CH	TFA	494.26
26	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	506.13
27	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	484.27
28	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	480.24




No.	m	n	R1	R3	R4	R5	L	R2	v	w	Y	Z	Salt	LCMS MH ⁺
29	1	1	H	H	H	H		Et	CH	CH	CH	CH	TFA	481.25
30	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	501.21
31	1	1	H	H	H	H		Et	CH	CH	CH	CH	TFA	473.27
32	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	480.24






No.	m	n	R1	R3	R4	R5	L	R2	v	w	Y	Z	Salt	LCMS MH ⁺
33	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	480.23
34	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	494.25
35	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	480.26
36	1	1	H	H	H	H		Et	CH	CH	CH	CH	TFA	480.24

No.	m	n	R1	R3	R4	R5	L	R2	v	w	Y	Z	Salt	LCMS MH ⁺
37	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	483.23
38	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	486.2
39	1	0	H	H	H			Et	CH	CH	CH	CH	TFA	520.28
40	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	548.29

No.	m	n	R1	R3	R4	R5	L	R2	v	w	Y	Z	Salt	LCMS MH ⁺
41	1	1	H	H	H	H		Et	CH	CH	CH	CH	TFA	473.22
42	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	480.23
43	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	494.26
44	1	1	H	H	H	Me		Et	CH	CH	CH	CH	TFA	508.26

No.	m	n	R1	R3	R4	R5	L	R2	v	w	Y	Z	Salt	LCMS MH ⁺
45	1	0	H	H	H	H		Et	CH	CH	CH	CH	TFA	494.25
46	1	1	H	H	H	H		Et	CH	CH	CH	CH	TFA	479.15
47	1	1	H	Me	H	H		Et	CH	CH	CH	CH	-	494.23
48	0	1	H	H	H	H		Et	CH	CH	CH	CH	-	466.0

No.	m	n	R1	R3	R4	R5	L	R2	v	w	Y	Z	Salt	LCMS MH ⁺
49	3	1	H	H	H	H		Et	CH	CH	CH	CH	-	508.0
50	1	1	Me	H	H	H		Et	CH	CH	CH	CH	HCl	494.0
51	1	1	H	H	H	H			CH	CH	CH	CH	TFA	506
52	1	1	H	H	H	H			CH	CH	CH	CH	TFA	520

No.	m	n	R1	R3	R4	R5	L	R2	v	w	Y	Z	Salt	LCMS MH ⁺
53	1	1	H	H	H	H		Et	CH	CH	CH	N	TFA	481
54	1	1	H	H	H	H			CH	CH	CH	CH	-	524
55	1	3	H	H	H	H		Et	CH	CH	CH	CH	HCl	507
56	1	2	H	Me	H	H		Et	CF	CH	CH	CH	-	518.3

Pharmacological tests were conducted on the compounds according to the invention to determine their inhibitory effect on protein with tyrosine kinase activity.

As an example, their inhibitory effects on the tyrosine kinase activity of PDGF-R
5 and/or Flt-3 were measured in vitro in cellular models.

The inhibitory activity with respect to PDGF or Flt-3 receptors is given by the concentration that inhibits 50% of the proliferation activity of cells Baf3 tel/PDGF or MV4-11, respectively.

10

Measurement of inhibition of the tyrosine kinase activity of the receptor to PDGF beta (PDGF-R β) (Baf-3 tel/PDGFR β):

This test consists of evaluating the effects of the compounds on the tyrosine kinase activity of the PDGF beta receptor.

15

The inhibitory effect of the compounds according to the invention on the tyrosine kinase activity of the PDGF-R receptor was evaluated on the murine haematopoietic cell line BaF/3 transfected with a plasmid coding for the fusion protein Tel/PDGF-R beta. This fusion protein is found in chronic myeloid myelomonocytic leukaemias (CMML). It comprises the N-terminal part of the transcription factor Tel
20 and the transmembrane and intracellular part of the PDGF-R beta receptor. This fusion protein is present in dimerized form (presence of an oligomerization domain in the N-terminal part of Tel) and accordingly leads to the constitutive activity of the kinase domain of PDGF-R beta. This line BaF3 Tel/PDGF has been described several times in the literature and notably in detail in the article of M CARROLL et al., PNAS,
25 1996, 93, 14845-14850, M CARROLL et al., Blood 2002, 99, 14845-14850.

The BaF3 Tel/PDGF cells are washed with phosphate buffer and seeded in 96-well plates, at a density of $5 \cdot 10^4$ cells/ml (100 μ l per well), in RPMI 1640 containing 10% of FCS, in the presence or absence of the test compounds. After incubation for 72 h, the viable cells are quantified by measurement of cellular ATP using the
30 CellTiter-Glo[®] kit (Promega, Cat G7571). The cells are treated according to the instructions given by the supplier of the kit and the luminescence is measured with a Luminoskan (Ascent, Labsystem) with the following parameters: measurement: single; integration time: 1000 ms, lag time: 5 s.

It thus appears that the compounds according to the invention have an inhibitory activity on the tyrosine kinase activity of PDGF-R beta. This activity is given by the concentration that inhibits 50% of the proliferation of Baf3 tel/PDGF cells (IC_{50}). The

5 IC_{50} values of the compounds according to the invention are below 1.0 μ M.

For example, compounds No. 2, 8, 9, 10, 14, 20, 27, 43, 50, 51, 52, 55 showed an IC_{50} of 7.9, 2, 9.8, 2.5, 2.4, 8, 2, 1.4, 6.6, 8.9, 13.6, 5.9 nM respectively in the test for measuring the tyrosine kinase activity of the PDGF receptor.

10 In addition to their properties of inhibition of PDGF-R tyrosine kinase, it also appears that compounds according to the invention display properties of inhibition of the tyrosine kinase activity of the Flt-3 receptor, as described below.

15 **Measurement of inhibition of the tyrosine kinase activity of the Flt-3 receptor**

The inhibitory effect of the compounds according to the invention on the tyrosine kinase activity of the Flt-3 receptor was evaluated on the MV4-11 cell line, a line established from a leukaemia of the AML type and bearing a constitutively active
20 mutant Flt3ITD. The inhibitory activity is correlated with inhibition of cell growth, according to the protocols described by SPIEKERMANN, K. et al., Blood, 2003, 101, (4) 1494-1504 and O'FARRELL, A.-M. et al., Blood, 2003, 101, (9) 3597-3605.

The MV4-11 cells are washed with PBS buffer and seeded in 96-well plates, at a density of 1.10^5 cells/ml (100 μ l per well), in RPMI 1640 containing 10% of FCS, in
25 the presence or absence of the test compounds. After incubation for 72 h, viable cells are quantified by measurement of cellular ATP using the CellTiter-Glo[®] kit (Promega, Cat G7571). The cells are treated according to the instructions given by the supplier of the kit and the luminescence is measured using a Luminoskan (Ascent, Labsystem) with the following parameters: measurement: single; integration time: 1000 ms, lag
30 time: 5 s.

The inhibitory activity with respect to the Flt-3 receptor is given by the concentration that inhibits 50% of the proliferation of the MV4-11 cells. It thus appears that the compounds according to the invention have an inhibitory activity on the tyrosine kinase activity of the Flt-3 receptor with IC_{50} values below 1.0 μ M.

For example, compounds No. 8, 20, 26, 27, 32, 42, 43, 50 showed an IC_{50} of 52, 26, 95, 30, 69, 84, 19, 115 nM respectively, in the test for measuring the tyrosine kinase activity of the Flt-3 receptor.

- 5 The compounds according to the invention are therefore inhibitors of protein kinases, notably of the tyrosine kinase receptors PDGF alpha and beta and, for some of them, also of the Flt-3 tyrosine kinase receptor.

10 Thus, according to one of the objects of the present invention, the compounds of formula (I) display very interesting activity of inhibition of phosphorylation of the kinase domain of the PDGF-R beta receptor in BaF3 Tel/PDGF cells, induced by the inhibitory activity of the product present in the plasma of the treated animals.

15 The compounds according to the invention are therefore inhibitors of protein kinases, notably of the tyrosine kinase receptors PDGF alpha and beta and, for some of them, also of the Flt-3 tyrosine kinase receptor.

20 The compounds according to the invention can therefore be used for preparing medicinal products, in particular medicinal products that are inhibitors of protein kinases.

 The medicinal products are inhibitors of protein kinase, notably medicinal products that are inhibitors of the PDGF-R tyrosine kinase receptor and optionally of the Flt-3 tyrosine kinase receptor.

- 25 Thus, according to another of its aspects, the invention relates to medicinal products that comprise a compound of formula (I), or a salt of addition of the latter to a pharmaceutically acceptable acid, or a solvate of the compound of formula (I).

30 These medicinal products find application in therapeutics, notably in the treatment of diseases associated with the activity of protein kinases and notably proliferative diseases such as cancers with liquid tumours, chronic or acute leukaemias, lymphocytic lymphomas, Hodgkin's disease, myeloproliferative syndromes and myelodysplastic syndromes.

These medicinal products also find application in therapeutics in the treatment of proliferative diseases such as cancers with solid tumours comprising lung cancers (NSCLC), cancers of bone, pancreas, skin, Kaposi syndrome, intraocular melanomas, cancers associated with the sexual organs comprising cancer of the breast, uterus, cervix, ovary, endometrium, vagina, vulva, urethra, penis, prostate, carcinomas of the fallopian tubes, cancers of the gastrointestinal stromal tumour type (abbreviation: GIST) comprising cancers of the anal region, rectum, small intestine, colon, stomach, oesophagus, cancers of endocrine glands, thyroid, parathyroid or adrenal glands, soft tissue sarcomas, Ewing sarcomas, osteosarcomas, dermatofibrosarcomas and other fibrosarcomas, cancers of the bladder or kidney, neoplasms of the central nervous system, tumours of the vertebral column and desmoids, gliomas of the brainstem and glioblastomas, pituitary adenomas and metastases thereof.

Another aspect of the invention comprises a combination between at least one compound according to the invention and at least one chemotherapy agent.

In fact, the compounds of the present invention can be used alone or mixed with at least one chemotherapy agent, which can be selected from cytotoxic agents and/or antiangiogens. For example, the antiangiogenic agents can be a compound that inhibits the kinase activity of VEGF-R or a compound that is an antagonist of a growth factor.

It is also possible to combine the compounds according to the invention with a radiation treatment.

The combinations of the compounds of the invention with the aforementioned chemotherapeutic agents and/or radiation are another subject of the present invention.

The aforementioned chemotherapeutic agents and/or radiation can be administered simultaneously, separately or sequentially. The treatment will be adapted by the practitioner according to the patient to be treated.

These medicinal products also find application in therapeutics, in the treatment of non-

malignant proliferative diseases such as restenosis, atherosclerosis, thrombosis, heart failure, cardiac hypertrophy, pulmonary arterial hypertension, fibrosis, diabetic nephropathy, glomerulonephritis, chronic pyelonephritis, haemangiomas, autoimmune diseases such as psoriasis, sclerodermatitis, immunosuppression (transplant rejection for example), pathologies associated with the eye such as post-operative fibrosis or age-related macular degeneration.

According to another of its aspects, the present invention relates to pharmaceutical compositions comprising, as active principle, a compound according to the invention. These pharmaceutical compositions contain an effective dose of at least one compound according to the invention, or a pharmaceutically acceptable salt of the latter, or a solvate of said compound, as well as at least one pharmaceutically acceptable excipient.

Said excipients are selected depending on the pharmaceutical form and desired method of administration, from the usual excipients that are known by a person skilled in the art.

In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, intratracheal, intranasal, transdermal or rectal administration, the active principle of formula (I) above, or optionally a salt or solvate thereof, can be administered in the unit dosage form, mixed with conventional pharmaceutical excipients, to animals and to human beings for prophylaxis or treatment of the aforementioned disorders or diseases.

The appropriate unit dosage forms comprise the forms for administration by the oral route, such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, forms for sublingual, buccal, intratracheal, intraocular, intranasal administration, administration by inhalation, forms for topical, transdermal, subcutaneous, intramuscular or intravenous administration, forms for rectal administration and implants. For topical application, the compounds according to the invention can be used in creams, gels, ointments or lotions.

As an example, a unit dosage form of a compound according to the invention in tablet form can comprise the following components:


71

	Compound according to the invention	50.0 mg
	Mannitol	223.75 mg
	Croscarmellose sodium	6.0 mg
	Maize starch	15.0 mg
5	Hydroxypropyl methylcellulose	2.25 mg
	Magnesium stearate	3.0 mg

According to another of its aspects, the present invention also relates to a method of treatment of the aforementioned pathologies comprising the administration, 10 to a patient, of an effective dose of a compound according to the invention or one of its pharmaceutically acceptable salts or solvates.

CLAIMS

1. Compound corresponding to formula (I):



5 in which,

R1 represents a hydrogen atom or a (C₁-C₄)alkyl group;

R2 represents a group -(CH₂)_n-B where:

- n'=0, 1, 2, 3 or 4; and
- 10 • B represents (i) a (C₃-C₅)cycloalkyl group or a (C₁-C₄)alkyl group, said group being optionally substituted with one or more fluorine atoms, or (ii) a (C₁-C₄)alkoxy group;

Y, Z, V and **W** represent, independently of one another:

- 15 • a -CH- group,
- a carbon atom optionally substituted with a group R7, said group R7 representing a (C₁-C₄)alkyl group or a halogen atom,
- a heteroatom such as a nitrogen atom, a sulphur atom or an oxygen atom, or
- 20 • no atom,

it being understood that the ring in which V, W, Y and Z are comprised is a ring comprising 5 or 6 ring members, it being understood that the dotted lines in said ring indicate that the resultant ring is an aromatic ring and it being understood that said ring comprises 0, 1 or 2 heteroatoms;

25

R3 and **R4** represent, independently of one another, groups that may be identical or different, R3 and R4 being selected from:

- a hydrogen atom; and

- a linear (C₁-C₄)alkyl group;

or **R3** and **R4** form, together with the carbon to which they are bound, a (C₃-C₅)cycloalkyl group;

5 **m** is an integer equal to 1, 2, 3 or 4;

R5 represents a hydrogen atom or a (C₁-C₄)alkyl group;

R6 represents a group -(CH₂)_n-L in which:

- 10 • n= 0, 1, 2 or 3, and
- **L** is a group selected from the following groups:
- an aryl comprising 6 carbon atoms;
 - a heteroaryl comprising between 5 and 6 ring members and comprising at least one heteroatom selected from nitrogen, oxygen and sulphur;
 - a saturated heterocycle comprising 5, 6 or 7 ring members and comprising at least one heteroatom selected from nitrogen and oxygen, said heterocycle being optionally a lactam;
- 15 said aryl, heteroaryl or heterocyclic group being optionally
- 20 substituted with at least one substituent selected from (i) linear or branched (C₁-C₄)alkyl groups, (ii) (C₃-C₅)cycloalkyl groups, (iii) halogen atoms, (iv) aryls and (v) benzyl;

 it being understood that when **L** is a heteroaryl or a heterocycle, said heteroaryl or heterocycle comprising at least one nitrogen atom, the latter

25 can optionally be substituted with said substituent;

or **R5** and **R6** form, together with the nitrogen atom to which they are bound, a heterocyclic group, optionally substituted with at least

- a heteroaryl, or
 - a (C₁-C₃)alkyl group, which can itself be substituted with a heterocycle comprising 5 or 6 atoms and comprising at least one heteroatom selected from nitrogen and oxygen, it being understood that when it is a heterocycle comprising at least one nitrogen atom, the latter can optionally be substituted;
- 30

said compound of formula (I), its enantiomers and diastereoisomers, including mixtures thereof, being in the form of a base or a salt of acid addition and/or in the form of solvate.

5

2. Compound according to the preceding claim, characterized in that R6 represents a group $-(CH_2)_n-L$ in which:

- $n = 0, 1, 2$ or 3 , and
- L is a group selected from the following groups:

10

- a heteroaryl comprising 5 ring members and comprising (i) 2 heteroatoms selected, independently of one another, from nitrogen, oxygen and sulphur, or (ii) 3 heteroatoms selected, independently of one another, from nitrogen and sulphur,

15

- a heteroaryl comprising 6 ring members and comprising 1 or 2 heteroatom(s),

- a heterocycle comprising 5 ring members and comprising a heteroatom selected from nitrogen and oxygen, said heterocycle being optionally a lactam, and

20

- a heterocycle comprising 6 ring members and comprising 2 heteroatoms selected from nitrogen and oxygen,

said heteroaryl group or heterocycle being optionally substituted with at least one substituent selected from (i) linear or branched (C_1-C_4) alkyl groups, (ii) (C_3-C_5) cycloalkyl groups, (iii) halogen atoms, (iv) aryls and (v) benzyl,

it being understood that when L is a heteroaryl or a heterocycle, said heteroaryl or heterocycle comprising at least one nitrogen atom, the latter can optionally be substituted with said substituent.

3. Compound according to any one of the preceding claims, characterized in that L is:

30

- a heteroaryl comprising 6 ring members selected from pyridine, pyrazine, pyridazine, pyrimidine;
- an aryl such as phenyl, or
- a heteroaryl comprising 5 ring members selected from thiazole, imidazole, pyrazole, isoxazole and 1,3,4-thiadiazole, or

- a saturated heterocycle comprising 5 ring members selected from pyrrolidine, tetrahydrofuran and 2-oxo-pyrrolidine or
- a saturated heterocycle comprising 6 ring members selected from morpholine, piperazine, piperidine,

5

said aryl, heteroaryl or heterocyclic group being optionally substituted with at least one substituent selected from (i) linear or branched (C₁-C₄)alkyl groups, (ii) (C₃-C₅)cycloalkyl groups and (iii) aryls,

it being understood that when L is a heteroaryl or a heterocycle, said heteroaryl or
10 heterocycle comprising at least one nitrogen atom, the latter can optionally be substituted with said substituent.

4. Compound according to any one of the preceding claims, characterized in that L is selected from:

- 15 • pyridine, optionally substituted with at least one linear or branched (C₁-C₄)alkyl group,
- morpholine, optionally substituted with at least (i) a (C₃-C₅)cycloalkyl group or (ii) a linear or branched (C₁-C₄)alkyl group,
- a pyrrolidine, optionally substituted with at least (i) a linear or branched (C₁-C₄)alkyl group, or (ii) a benzyl,
- 20 • a thiazole, optionally substituted with at least (i) a linear or branched (C₁-C₄)alkyl group, or (ii) a chlorine atom,
- an imidazole, optionally substituted with at least one linear or branched (C₁-C₄)alkyl group,
- 25 • a 2-oxo-pyrrolidine,
- a 1,3,4-thiadiazole, optionally substituted with at least (i) a linear or branched (C₁-C₄)alkyl group, or (ii) a (C₃-C₅)cycloalkyl group,
- an isoxazole, optionally substituted with at least one linear or branched (C₁-C₄)alkyl group,
- 30 • a pyrazole, optionally substituted with at least one linear or branched (C₁-C₄)alkyl group,
- a pyrazine,
- an isothiazole, optionally substituted with at least one linear or branched (C₁-C₄)alkyl group,

- a phenyl,
- a tetrahydrofuran,

it being understood that when **L** is a heteroaryl or a heterocycle, said heteroaryl or heterocycle comprising at least one nitrogen atom, the latter can optionally be substituted.

5 **5.** Compound according to any one of the preceding claims, characterized in that **R5** represents a hydrogen atom or a methyl.

10 **6.** Compound according to any one of the preceding claims, characterized in that:

- **m** is equal to 1 or 3, and/or
- **R3** and **R4** represent, independently of one another, groups that may be identical or different, **R3** and **R4** being selected from:
 - a hydrogen atom, and
 - a methyl.

7. Compound according to any one of the preceding claims, characterized in that **Y**, **Z**, **V** and **W** represent, independently of one another:

- a group $-\text{CH}-$;
- a carbon atom substituted with a group **R7**, said group **R7** representing a $(\text{C}_1\text{-C}_4)$ alkyl group or a fluorine atom; or
- a heteroatom such as a nitrogen atom, a sulphur atom or an oxygen atom, advantageously a nitrogen atom.

25 **8.** Compound according to any one of the preceding claims, characterized in that **R1** represents a hydrogen atom or a methyl.

9. Compound according to any one of the preceding claims, characterized in that **R2** represents a group $-(\text{CH}_2)_n\text{-B}$ where:

- $n'=0, 1$ or 3 ; and/or
- **B** represents (i) a $(\text{C}_3\text{-C}_5)$ cycloalkyl group, (ii) a $(\text{C}_1\text{-C}_4)$ alkyl group or (iii) a $(\text{C}_1\text{-C}_4)$ alkoxy group.

10. Compound according to any one of Claims 1 and 6 to 9, characterized in that **R5** and **R6** form, together with the nitrogen atom to which they are bound, a heterocyclic group, optionally substituted with at least

- a heteroaryl, advantageously a pyridine; or
- 5 • a (C₁-C₃)alkyl group, which can itself be substituted with a heterocycle comprising 5 or 6 atoms and comprising at least one heteroatom selected from nitrogen and oxygen, advantageously it is a C₁alkyl group, itself substituted with a heterocycle comprising 5 atoms including a nitrogen atom.

10

11. Compound according to any one of the preceding claims, characterized in that it is in the form of a base or a salt of addition to an acid such as hydrochloric acid or trifluoroacetic acid.

15 12. Compound according to any one of the preceding claims, characterized in that it is:

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-2-yl-acetamide (compound 1);

20 2-{6-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-pyridin-3-yl}-N-pyridin-2-yl-acetamide (compound 2);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-cyclopropyl-morpholin-3-ylmethyl)-acetamide (compound 3);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-isopropyl-morpholin-3-ylmethyl)-acetamide (compound 4);

25 2-Amino-1-ethyl-3-(1H-imidazol-2-yl)-7-{4-[2-oxo-2-((S)-2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-ethyl]-phenyl}-1H-[1,8]naphthyridin-4-one (compound 5);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-pyridin-4-yl-ethyl)-acetamide (compound 6);

30 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-methyl-N-(2-pyridin-4-yl-ethyl)-acetamide (compound 7);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-methyl-thiazol-2-yl)-acetamide (compound 8);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-3-methyl-phenyl}-N-(1-ethyl-pyrrolidin-2-ylmethyl)-acetamide (compound 9);

- 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(6-methyl-pyridin-3-yl)-acetamide (compound 10);
- 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(1,3-dimethyl-1H-pyrazol-4-ylmethyl)-acetamide (compound 11);
- 5 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-thiazol-2-ylmethyl-acetamide (compound 12);
- 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-oxo-pyrrolidin-2-ylmethyl)-acetamide (compound 13);
- 10 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-methyl-[1,3,4]thiadiazol-2-yl)-acetamide (compound 14);
- 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-[1,3,4]thiadiazol-2-yl-acetamide (compound 15);
- 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3-methyl-isoxazol-5-yl)-acetamide (compound 16);
- 15 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-acetamide (compound 17);
- 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-methyl-thiazol-2-yl)-acetamide (compound 18);
- 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide (compound 19);
- 20 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-cyclopropyl-[1,3,4]thiadiazol-2-yl)-acetamide (compound 20);
- 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-pyridin-3-yl-ethyl)-acetamide (compound 21);
- 25 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2,5-dimethyl-2H-pyrazol-3-ylmethyl)-acetamide (compound 22);
- 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(1-methyl-1H-imidazol-4-ylmethyl)-acetamide (compound 23);
- 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyrazin-2-yl-acetamide (compound 24);
- 30 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-pyridin-2-yl-ethyl)-acetamide (compound 25);
- 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-chloro-thiazol-2-yl)-acetamide (compound 26);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3,4-dimethyl-isoxazol-5-yl)-acetamide (compound 27);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-methyl-pyridin-4-yl)-acetamide (compound 28);

5 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyrazin-2-ylmethyl-acetamide (compound 29);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(5-ethyl-[1,3,4]thiadiazol-2-yl)-acetamide (compound 30);

10 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(tetrahydro-furan-2-ylmethyl)-acetamide (compound 31);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3-methyl-pyridin-2-yl)-acetamide (compound 32);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-methyl-pyridin-2-yl)-acetamide (compound 33);

15 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4,6-dimethyl-pyridin-2-yl)-acetamide (compound 34);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(6-methyl-pyridin-2-yl)-acetamide (compound 35);

20 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-3-ylmethyl-acetamide (compound 36);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(2-ethyl-2H-pyrazol-3-yl)-acetamide (compound 37);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3-methyl-isothiazol-5-yl)-acetamide (compound 38);

25 2-Amino-1-ethyl-3-(1H-imidazol-2-yl)-7-{4-[2-oxo-2-(2-pyridin-3-yl-pyrrolidin-1-yl)-ethyl]-phenyl}-1H-[1,8]naphthyridin-4-one (compound 39);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(1-benzyl-pyrrolidin-3-yl)-acetamide (compound 40);

30 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-[(S)-1-(tetrahydro-furan-2-yl)methyl]-acetamide (compound 41);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-methyl-pyridin-3-yl)-acetamide (compound 42);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(4-ethyl-pyridin-2-yl)-acetamide (compound 43);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-ethyl-N-pyridin-4-ylmethyl-acetamide (compound 44);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(6-ethyl-pyridin-2-yl)-acetamide (compound 45);

5 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-benzyl-acetamide (compound 46);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-propionamide (compound 47);

4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-N-pyridin-4-ylmethyl-benzamide (compound 48);

4-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-butyramide (compound 49);

2-{4-[7-Amino-8-ethyl-6-(4-methyl-1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide (compound 50);

15 2-{4-[7-Amino-8-cyclopropylmethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide (compound 51);

2-{4-[7-Amino-8-cyclopentyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide (compound 52);

20 2-{5-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-pyridin-2-yl}-N-pyridin-4-ylmethyl-acetamide (compound 53);


2-{4-[7-Amino-6-(1H-imidazol-2-yl)-8-(3-methoxy-propyl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-pyridin-4-ylmethyl-acetamide (compound 54);

2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-phenyl}-N-(3-phenyl-propyl)-acetamide (compound 55);


25 2-{4-[7-Amino-8-ethyl-6-(1H-imidazol-2-yl)-5-oxo-5,8-dihydro-[1,8]naphthyridin-2-yl]-2-fluoro-phenyl}-N-(1-ethyl-pyrrolidin-2-ylmethyl)-acetamide (compound 56).

13. Process for preparing a compound of formula (I) according to any one of Claims 1 to 12, characterized in that (i) a compound of the following formula (VII):

81




in which Pg represents a protecting group and X represents a halogen atom,
 is reacted according to a Suzuki coupling reaction with (ii) a boronic acid or a boronic
 5 ester of pinacol of formula (IXa):




in which G represents a group -NR5R6 or G represents a group
 -OEt;

10 in order to obtain respectively (iii) a compound of the following formula (X):




in which G represents a group -NR5R6 and Pg is as defined previously;
 or (iv) a compound of the following formula (XI):




in which G represents a group -OEt and Pg is as defined previously;
it being understood that m, R₁, R₂, R₃, R₄, R₅, R₆, V, W, Y and Z are as defined in Claim 1.


- 5 14. Process for preparing a compound of formula (I) according to any one of Claims 1 to 12, characterized in that (i) a compound of formula (VIII):



- 10 in which Pg represents a protecting group;
is reacted according to a Stille coupling reaction with (ii) an aryl or heteroaryl halide of the following formula (IXb):




- 15 in which G represents a group -OEt or G represents a group -NR₅R₆ and X represents a halogen atom;
in order to obtain (iii) a compound of the following formula (X):



- 20 for which G represents a group -NR₅R₆ and Pg is as defined previously;
or (iv) a compound (XI) of the following formula:

83



for which G represents a group -OEt,


it being understood that m, R₁, R₂, R₃, R₄, R₅, R₆, V, W, Y and Z are as defined in

5 Claim 1.

15. Process for preparing a compound of formula (I) according to one of Claims 13 or 14, characterized in that the compound (XI) for which G represents a group -OEt then

undergoes a stage of saponification and then a stage of peptide coupling with the

10 amine HNR₅R₆, giving the compound (XIII) of the following formula:



it being understood that Pg represents a protecting group and that m, R₁, R₂, R₃, R₄, R₅, R₆, V, W, Y and Z are as defined in Claim 1.

15 16. Medicinal product, characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to 12, or a salt of addition of this compound to a pharmaceutically acceptable acid, or a solvate of the compound of formula (I).

17. Pharmaceutical composition, characterized in that it comprises a compound of
20 formula (I) according to any one of Claims 1 to 12, or a pharmaceutically acceptable salt, a solvate of this compound, as well as at least one pharmaceutically acceptable excipient.

18. Use of a compound of formula (I) according to any one of Claims 1 to 12 for

preparing a medicinal product intended for treating diseases linked to the activity of protein kinases, said compound of formula (I) inhibiting the tyrosine kinase activity of PDGF-R, in particular PDGF-R beta, in Baf3 tel/PDGF cells and/or inhibiting the tyrosine kinase activity of Flt-3 in MV4-11 cells.

5

19. Use of a compound of formula (I) according to any one of Claims 1 to 12 for preparing a medicinal product intended for the treatment of proliferative diseases such as cancers with liquid tumours, chronic or acute leukaemias, lymphocytic lymphomas, Hodgkin's disease, myeloproliferative syndromes and myelodysplastic syndromes.

10

20. Use of a compound of formula (I) according to any one of Claims 1 to 12 for preparing a medicinal product intended for the treatment of proliferative diseases such as cancers with solid tumours comprising lung cancers (NSCLC), cancers of bone, pancreas, skin, Kaposi syndrome, intraocular melanomas, cancers associated with sexual organs comprising cancer of the breast, uterus, cervix, ovary, endometrium, vagina, vulva, urethra, penis, prostate, carcinomas of the fallopian tubes, cancers of the gastrointestinal stromal tumour type (abbreviation: GIST) comprising cancers of the anal region, rectum, small intestine, colon, stomach, oesophagus, cancers of endocrine glands, thyroid, parathyroid or adrenal glands, soft tissue sarcomas, Ewing sarcomas, osteosarcomas, dermatofibrosarcomas and other fibrosarcomas, cancers of the bladder or kidney, neoplasms of the central nervous system, tumours of the vertebral column and desmoids, gliomas of the brainstem and glioblastomas, pituitary adenomas and metastases thereof.

21. Use of a compound of formula (I) according to any one of Claims 1 to 12 for preparing a medicinal product intended for the treatment of non-malignant proliferative diseases such as restenosis, atherosclerosis, thrombosis, heart failure, cardiac hypertrophy, pulmonary arterial hypertension, fibrosis, diabetic nephropathy, glomerulonephritis, chronic pyelonephritis, haemangiomas, auto-immune diseases such as psoriasis, sclerodermatitis, immunosuppression, pathologies of the eye such as post-operative fibrosis and age-related macular degeneration.

22. Compound of formula (I) according to any one of Claims 1 to 12 for preparing a medicinal product intended for the treatment of proliferative diseases such as cancers

with liquid tumours, chronic or acute leukaemias, lymphocytic lymphomas, Hodgkin's disease, myeloproliferative syndromes and myelodysplastic syndromes.

23. Compound of formula (I) according to any one of Claims 1 to 12 for preparing a
5 medicinal product intended for the treatment of proliferative diseases such as cancers with solid tumours comprising lung cancers (NSCLC), cancers of bone, pancreas, skin, Kaposi syndrome, intraocular melanomas, cancers associated with sexual organs comprising cancer of the breast, uterus, cervix, ovary, endometrium, vagina, vulva, urethra, penis, prostate, carcinomas of the fallopian tubes, cancers of the
10 gastrointestinal stromal tumour type (abbreviation: GIST) comprising cancers of the anal region, rectum, small intestine, colon, stomach, oesophagus, cancers of endocrine glands, thyroid, parathyroid or adrenal glands, soft tissue sarcomas, Ewing sarcomas, osteosarcomas, dermatofibrosarcomas and other fibrosarcomas, cancers of the bladder or kidney, neoplasms of the central nervous system, tumours of the
15 vertebral column and desmoids, gliomas of the brainstem and glioblastomas, pituitary adenomas and metastases thereof.

24. Compound of formula (I) according to any one of Claims 1 to 12 for preparing a medicinal product intended for the treatment of non-malignant proliferative diseases
20 such as restenosis, atherosclerosis, thrombosis, heart failure, cardiac hypertrophy, pulmonary arterial hypertension, fibrosis, diabetic nephropathy, glomerulonephritis, chronic pyelonephritis, haemangiomas, auto-immune diseases such as psoriasis, sclerodermatitis, immunosuppression, pathologies associated with the eye such as post-operative fibrosis or age-related macular degeneration.

25

25. Combination of at least one compound of formula (I) according to any one of Claims 1 to 12 with at least one chemotherapy agent.